THE IDENTIFICATION AND CHARACTERIZATION OF
NOVEL PERSISTENCE GENES IN
CHLAMYDIA TRACHOMATIS

Matthew Kazuyuki Muramatsu

Submitted to the faculty of the University Graduate School
in partial fulfillment of the requirements
for the degree
Doctor of Philosophy
in the Department of Microbiology and Immunology,
Indiana University

March 2017
Accepted by the Graduate Faculty, Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy.

David E. Nelson, Ph.D., Chair

Byron E. Batteiger M.D.

C. Henrique Serezani Ph.D.

Stanley M. Spinola, M.D.

William J. Sullivan, Jr., Ph.D.

November 30, 2016
DEDICATION

I would like to dedicate this dissertation to my family for their support not only during my time in graduate school but throughout my entire life. I will always be eternally grateful for their never-ending sacrifice and how they have inspired me to work hard to achieve my goals.
ACKNOWLEDGEMENTS

I would like to thank my mentor for his patience and allowing me the opportunity to present my scientific discoveries in papers and at conferences. My committee for providing invaluable guidance throughout my time in graduate school, and for setting me on the path to becoming a better scientific writer. The amazing secretaries who helped to keep me on track and moving toward my degree. Lastly, my friends and lab mates for their personal and scientific advice, and generally being there to help me blow off steam.
Matthew Kazuyuki Muramatsu

THE IDENTIFICATION AND CHARACTERIZATION OF NOVEL PERSISTENCE GENES IN *CHLAMYDIA TRACHOMATIS*

*Chlamydia trachomatis* is an obligate intracellular bacterial pathogen that can infect the eyes, genital tract, and disseminate to lymph nodes in humans. Many *C. trachomatis* infections are clinically asymptomatic and can become chronic if left untreated. When humans are infected with *C. trachomatis*, a cytokine that is produced is interferon-gamma (IFN-γ). *In vitro*, IFN-γ stimulates expression of the host enzyme indoleamine 2,3-dioxygenase. This enzyme converts free intracellular tryptophan to N-formylkynurenine. Tryptophan starvation induces *C. trachomatis* to enter a viable-but-nonculturable state termed persistence, which has been proposed to play a key role in chronic *Chlamydial* disease. To circumvent host induced tryptophan depletion, urogenital strains of *C. trachomatis* encode a functional tryptophan synthase (TS). TS synthesizes tryptophan from indole and serine, allowing *Chlamydia* to reactivate from persistence. Transcriptomic analysis revealed *C. trachomatis* differentially regulates hundreds of genes in response to tryptophan starvation. However, genes that mediate entry, survival, and reactivation from persistence remain largely unknown. Using a forward genetic screen, we identified six Susceptible to IFN-γ mediated Persistence (Sip) mutants that have diminished capacities to reactivate from persistence with indole. Mapping the deleterious persistence alleles in three of the Sip mutants revealed that only one of the mutants had a mutation in TS. The two other Sip mutants mapped had
mutations in CTL0225, a putative integral membrane protein, and CTL0694, a putative oxidoreductase. Neither of these genes plays a known role in tryptophan synthesis. However, amino acid (AA) competitive inhibition assays suggest that CTL0225 may be involved in the transport of leucine, isoleucine, valine, cysteine, alanine, and serine. Additionally, metabolomics analysis indicates that all free amino acids are depleted in response to IFN-γ, making this amino acid transporter essential during persistence. Taken together we have identified two new chlamydial persistence genes that may play a role in chronic chlamydial disease.

David E. Nelson, Ph.D., Chair
# TABLE OF CONTENTS

- LIST OF TABLES .................................................................................................................. ix
- LIST OF FIGURES ................................................................................................................ x
- LIST OF ABBREVIATIONS .................................................................................................. xii

## CHAPTER I: INTRODUCTION

- Section I: A brief history of chlamydial disease ................................................................. 1
- Section II: Global prevalence of *C. trachomatis* infections ........................................... 2
- Section III: Intracellular development of *C. trachomatis* ............................................... 4
- Section IV: Chlamydial persistence ................................................................................... 7
- Section V: Chlamydial genetics ......................................................................................... 13

## CHAPTER II: RESEARCH GOALS/HYPOTHESIS .................................................................. 23

## CHAPTER III: MATERIALS AND METHODS ........................................................................ 24

## CHAPTER IV: Isolation and characterization of persistence mutants .................................... 45

## CHAPTER V: Characterization of CTL0225 ......................................................................... 71

## CHAPTER VI: Discussion ........................................................................................................ 90

## CHAPTER VII: Future Directions .......................................................................................... 101

## REFERENCES .......................................................................................................................... 107

## CURRICULUM VITAE
LIST OF TABLES

Table 1. Primers used in this study ................................................................. 39
Table 2. Plasmids used in this study ............................................................... 43
Table 3. Bacteria used in this study ............................................................... 44
Table 4. Mutations in Sip mutants ................................................................. 69
LIST OF FIGURES

Figure 1. Prevalence of active and suspected regions of trachoma in 2015 ........ 19
Figure 2. Sexually transmitted *C. trachomatis* infections in the US. ............ 20
Figure 3. *In vitro* *C. trachomatis* L2 life cycle.. ............................................. 21
Figure 4. IFN-γ mediated persistence ................................................................. 22
Figure 5. IFN-γ persistence screen ..................................................................... 36
Figure 6. Counterselection LGT......................................................................... 37
Figure 7. AA competitive inhibition screen......................................................... 38
Figure 8. *C. trachomatis* L2 was transformed with pGFP::SW2 ....................... 56
Figure 9. Secondary screening.......................................................................... 57
Figure 10. Sip mutants exhibit normal growth kinetics........................................ 58
Figure 11. Sip mutants make fewer EB following reactivation ......................... 59
Figure 12. Sip recombinants form similar numbers of inclusions as L2-GFP ....... 60
Figure 13. Sip mutant make smaller inclusions following reactivation ............. 61
Figure 14. Transmission electron microscopy of L2-GFP and Sip mutants ......... 62
Figure 15. Sip mutant EB production cannot be rescued by Trp or indole ........ 63
Figure 16. Genome replication is altered during Sip mutant reactivation......... 64
Figure 17. Sip 6 forms small inclusions in the presence of IFN-γ + Trp............. 65
Figure 18. Trp starvation alone induces Sip mutants to enter persistence......... 66
Figure 19. Sip1 TrpBP221S aligned to *Salmonella typhimurium* TS................ 67
Figure 20. Sip6 CTL0694P105L aligned to the crystal structure of *E. coli* CysJ. .... 68
Figure 21. G77E mutations alters CTL0225 membrane topology....................... 77
Figure 22. Sip2 is sensitive to high concentrations of Ile.................................. 78
Figure 23. Only Val reverses the Sip2 small inclusion phenotype...................... 79
Figure 24. Ala reverses formation of small inclusions induced by excess Ser .... 80
Figure 25. Ala reverses Sip2 small inclusion phenotype caused by Cys.............. 81
Figure 26. Sip2 forms two populations of inclusions when treated with Ser..... 82
Figure 27. Ala does not reverse small inclusion phenotype caused by Ile......... 83
Figure 28. Sip2 does not form large inclusions in the presence of Val + Ser..... 84
Figure 29. Free AA concentrations remain stable over time.......................... 85
Figure 30. Free AA decrease over time in IFN-\(\gamma\) treated HeLa cells........... 86
Figure 31. IFN-\(\gamma\) decreases free AA pools in HeLa cells........................ 87
Figure 32. \textit{C. trachomatis} increases some free AA pools.......................... 88
Figure 33. Free AAs are not increased during IFN-\(\gamma\) mediated persistence .... 89
LIST OF ABBREVIATIONS

ABA ............................................. Aminobutyric acid
Ala ............................................. Alanine
Amp ............................................. Ampicillin
ATc ............................................. Anhydrous tetracycline
BACTH ........................................ Bacterial two-hybrid
BCAA ........................................ Branched chained amino acids
Bp ............................................... Base pair
BpdI ........................................... 2,2’-bipyridyl
Bsd ............................................... Blasticidin S deaminase
BV ............................................... Bacterial vaginosis
Cat .............................................. Chloramphenicol acetyltransferase
CDC ............................................. Centers for disease control
CdsF ............................................. Chlamydia needle-forming protein
ChxR ............................................. Chlamydia mid-cycle transcription factor
COMC ........................................ Chlamydia outer membrane complex
Cys ............................................. Cysteine
CysJ ............................................. E. coli sulfite reductase subunit alpha
DAM ............................................. Deferoxamine mesylate
DMEM-10 ..................................... Dulbecco’s modified Eagle’s medium
DMEM-10G ................................... DMEM-10 supplemented with IFN-γ
DMEM-TF ..................................... DMEM-10 without tryptophan
EB ............................................... Chlamydia elementary body
EMS ............................................. Ethyl methanesulfonate
MD-76R

Diatrizoic acid

MOI

Multiplicity of infection

NEAA

Non-essential amino acids

PBPs

Penicillin binding proteins

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

PG

Peptidoglycan

Phe

Phenylalanine

PID

Pelvic inflammatory disease

PZ

Chlamydial plasticity zone

qPCR

Quantitative PCR

Rab1

Ras-related proteins in brain 1

Rab11

Ras-related proteins in brain 11

Rab4

Ras-related proteins in brain 4

Rab5

Ras-related proteins in brain 5

Rab7

Ras-related proteins in brain 7

Rab9

Ras-related proteins in brain 9

RB

Chlamydia reticulate body

RpoB

RNA polymerase subunit B

rSip

Recombinant Sip strain

Ser

Serine

Sip

Sensitive to IFN-γ induced persistence

SNAREs

Soluble NSF attachment protein receptor

SNAT

Small neutral amino acid transporter

Spc

Spectinomycin
SPG..............................Sucrose-phosphate glutamic acid buffer
STI..............................Sexually transmitted infections
T3SS............................Type three secretion system
TCA..............................Trichloroacetic acid
TEM..............................Transmission electron microscopy
TILLING........................Targeted induced local lesions in genomes
TL.................................Tryptophan limiting
Trp...............................Tryptophan
TrpA.............................Tryptophan synthase $\alpha$-subunit
TrpB.............................Tryptophan synthase $\beta$-subunit
TS...............................Tryptophan synthase
Val..............................Valine
VAMP4...........................Vesicle-associated membrane protein 4
VBNC............................Viable-but-non-culturable-state
WARS.............................Tryptophanyl-tRNA synthetase
WGS..............................Whole genome sequencing
WHO..............................World health organization
YcbX.............................E. coli base analog detoxification protein
ZeoR.............................Zeocin resistance
Chapter I: Introduction

Section I:

A brief history of chlamydial disease

*Chlamydia trachomatis* is an obligate intracellular bacterial pathogen that has been co-evolving with humans for thousands of years. Scarring in ancient Aboriginal Australian skulls, dating back to around 8000 BC, is the earliest evidence of chronic *C. trachomatis* eye infections [1]. Additionally, the ancient Egyptians were among the first to describe treatments for a Chlamydia-like disease known as *nehat* in the Ebers Papyrus around 1500 BC [2].

*C. trachomatis* is one of the most prolific human pathogens. The ebb and flow of human conquest and exploration have contributed to the global dissemination of *C. trachomatis*. Troops returning from the Napoleonic Wars (1803-1815) may have contributed to the spread of *C. trachomatis* from Egypt to Europe [3]. The fear of trachoma was so great that in 1897 the United States government classified *C. trachomatis* as a “loathsome and contagious disease” and increased screening of U.S immigrants in an attempt to control its spread [4].

In 1907, Halberstaedter and Prowazek noticed small inclusion bodies, later determined to be chlamydial inclusions, in the cytoplasm of cells from scrapings of apes and humans with trachoma [5]. Shortly after this, the detection of inclusion bodies in newborns with conjunctivitis [6] and people with non-gonococcal sexually transmitted disease [7, 8], suggested that there may be a link between ocular trachoma, neonatal conjunctivitis, and genital disease. Additionally, monkeys infected with material gathered from men and women presenting with non-gonococcal genital infections developed trachoma.
Results from these studies suggest that trachoma and non-gonococcal genital disease were caused by the same etiological agent, later classified as \textit{C. trachomatis}.

\textbf{Section II:}

\textit{Chlamydia trachomatis} infections

\textbf{Ocular chlamydial disease}

\textit{C. trachomatis} serovars differ in their tissue tropisms and pathogenic strategies. Serovars A-C are the etiological agents of trachoma and primarily infect the conjunctival epithelial cells in the eye. While trachoma is still a global public health problem, improvements in sanitation and hygiene have limited the spread of \textit{C. trachomatis} in the past several decades [10]. Currently, trachoma is only endemic in poor and rural locations of 42 countries located in Africa, Central and South America, Asia, Australia, and the Middle East (Figure 1).

Despite the fall in the global prevalence of trachoma, \textit{C. trachomatis} serovars A-C remain the leading cause of preventable blindness by an infectious agent. When left untreated, repeated infections can lead to conjunctival scarring, development of corneal opacities, and possible progression to trichiasis (i.e., inversion of the eyelashes), which can result in irreversible blindness. Approximately 7.2 million people live with advanced trachoma, while another 200 million are at risk by living in trachoma endemic areas. In 2015, roughly 54 million people were treated for conjunctival \textit{C. trachomatis} infections. The loss of productivity and treatment costs associated with trachoma was recently estimated at 8 billion dollars [11, 12], indicating trachoma is still a significant global health and economic burden.
Sexually transmitted chlamydial disease

Urogenital

*C. trachomatis* serovars D-K are sexually transmitted and typically cause urogenital infections. According to the World Health Organization (WHO), there are approximately 131 million new cases of sexually transmitted *C. trachomatis* infections each year [13]. In the United States, the most common sexually transmitted bacterial infection is *C. trachomatis*. National surveillance data, provided by the Centers for Disease Control and Prevention (CDC), indicate that rates of *C. trachomatis* infection were among the highest in Washington DC, Alaska, and the Virgin Islands (Figure 2).

In 2014, the CDC documented 1,441,789 new sexually transmitted *C. trachomatis* infections across the United States. However, they estimate that the annual number of urogenital *C. trachomatis* infections may be closer to 2.8 million per year because the majority of infections are asymptomatic in men and women (50% and 70% of all infections, respectively) [14]. When symptoms are present, men usually present with urethritis and less commonly with epididymitis [15]. Symptomatic women may present with Bartholinitis, cervicitis, and acute urethral syndrome [16]. Additionally, chronically infected women are at risk for pelvic inflammatory disease (PID), endometritis, and ectopic pregnancies [17, 18]. A smaller proportion of patients can also develop Reiter's syndrome (reactive arthritis) [19, 20]. The CDC recommends that *C. trachomatis* urogenital infections be treated with a single dose of 1 gram of azithromycin or 100 milligrams of doxycycline twice daily for seven days.
Rectal

*Chlamydia trachomatis* urogenital strains can also infect the rectum, most commonly in men who have sex with men. In heterosexuals, detection of rectal infections is not as common as urogenital tract infections. However, the frequency of rectal infections in heterosexuals may be higher than what is appreciated because screening the rectum for *Chlamydia trachomatis* is not standard practice unless patients have specific risk factors. *Chlamydia trachomatis* D-K rectal infections are usually asymptomatic. In contrast, *Chlamydia trachomatis* L1-L3 strains, which frequently infect the rectum, can cause severe disease and pathology [21].

While rectal infections with *Chlamydia trachomatis* D-K are rarer than urogenital infections in women, there is increasing concern that some apparent urogenital treatment failures may arise because of autoinoculation from the rectum [22, 23]. Additionally, a meta-analysis of rectal chlamydia treatment studies indicates doxycycline may be more efficacious than azithromycin for rectal *Chlamydia trachomatis* infections [24]. These studies suggest that *Chlamydia trachomatis* GI tract infections may be refractory to treatment with azithromycin and that GI tissues may be acting as a chlamydial reservoir contributing to apparent azithromycin treatment failure in women.

**Section III:**

**Intracellular development of Chlamydia trachomatis**

*In vitro chlamydial developmental lifecycle*

*Chlamydia trachomatis* is an obligate intracellular pathogen that has a biphasic life cycle (Figure 3). The extracellular, infectious forms of *Chlamydia* spp. are known as elementary bodies (EBs). EBs contain an electron dense nucleoid [25] that is enveloped in a protein shell known as the chlamydial outer membrane
complex (COMC). The COMC is primarily composed of three highly cross-linked cysteine-rich proteins OmpA, OmcA, and OmcB. These proteins are connected by disulfide bonds to form a semi-permeable lattice. [26-28] The COMC also contains “rosette structures” [29] that are thought to be composed of the chlamydial type III secretion system (T3SS) pores and the needle-forming protein, CdsF [30]. T3SS is a critical virulence factor that facilitates the injection of chlamydial proteins into host cells [31]. Ultrastructural analysis indicates that EBs have a polarized architecture and that CdsF associated needle-like structures form at the pole closest to host cells [32], suggesting that the T3SS plays a role in cellular invasion.

After an EB has successfully entered a host cell, the COMC is reduced [26], and EBs transition into reticulate bodies (RBs). Unlike EBs, RBs are non-infectious, metabolically active, and can replicate [31, 33, 34]. Genes necessary for RB replication and EB production are temporally regulated in *C. trachomatis* and fall into three rough categories called early, mid, and late genes [35-37].

Transcription of early genes begins 1 to 3 hours after *C. trachomatis* infection. Functions of early genes include suppressing transcription of late genes, macromolecular synthesis (transcription, translation, DNA replication), and setting up the nascent chlamydial inclusion [36]. During this time, EBs are also transitioning into RBs, and early inclusion membrane proteins (Incs) begin to decorate the nascent inclusion [38]. The majority of Incs share low primary sequence similarity; however, they are capable of forming similar secondary bilobed structures with N- and C- termini facing the cytoplasmic side of the inclusion membrane [39, 40]. Early Incs may prevent endocytic maturation of the chlamydial inclusion and fusion with lysosomes by preventing the
recruitment of early (Rab5) and late (Rab7 and Rab9) endocytic markers [41]. Additionally, the Inc protein CT850 plays a role in relocating the inclusion from the periphery of the cell to the peri-Golgi region, in a dynein-dependent manner [42, 43]. By relocating to the peri-Golgi region, RBs have access to nutrients from exocytic vesicles that promote growth and development of RB and the inclusion.

By eight hours post infection, the majority of *C. trachomatis* genes involved with replication, metabolism, and inclusion development begin to be expressed [44]. Incs expressed during mid-development may facilitate inclusion and chlamydial growth by recruiting host Rab proteins. Some Rab proteins that associate with the inclusion membrane include Rab4 and Rab11, which are involved in receptor recycling, and Rab1, which participates in vesicle trafficking from the endoplasmic reticulum (ER) to the Golgi [41]. Recruitment of these Rabs promotes the association of SNAREs, syntaxin6, and VAMP4 proteins. These proteins facilitate eukaryotic vesicle interactions and lead to the fusion of nutrient rich vesicles containing sphingomyelin and cholesterol with the chlamydial inclusion [45-47].

Late in development (>24h), most RBs have undergone 8 to 10 rounds of replication by binary fission [48] and a yet undefined asymmetric-polarized budding process [49, 50] and have begun to transition back into EBs. Increased late gene products may influence RB to EB transition. Known roles of late genes include DNA condensation, the formation of the COMC, and EB maturation. Late gene transcription has been shown to be inversely related to the expression of the early gene *euo*, which binds to late gene promoters and represses transcription [51]. Additionally, sigma-28 is a transcription factor that promotes late gene transcription [52].
Once RBs have transitioned into EBs, these are then released by host cell lysis or by extrusion of the entire chlamydial inclusion [53]. The release of EB from mature inclusions and subsequent host cell lysis is dependent on the plasmid gene pgp4. Pgp4 is a transcription factor that regulates chromosomal and plasmid genes. One of these genes is a T3S effector that destabilizes actin surrounding the chlamydial inclusion [54]. In addition to the destabilization of actin, chlamydial phospholipases, expressed during mid and late development [37], may weaken the inclusion membrane. In contrast to inclusion lysis, extrusion is an actin-dependent process that preserves the chlamydial inclusion and releases it without killing the host cell [55]. By manipulating the myosin phosphatase pathway, C. trachomatis hijacks phosphorylated myosin light chain 2 (MLC2), myosin light chain kinase (MLCK), and myosin II to extrude from the host cell [56].

Section IV:
Chlamydial persistence

Various stimuli can disrupt the C. trachomatis biphasic development cycle and induce C. trachomatis to enter a viable-but-non-culturable (VBNC) state termed persistence [48]. When this occurs, three phenotypes characterize persistent chlamydial forms. First, persistent chlamydia forms small inclusions that contain enlarged and non-dividing RB [48]. Second, these aberrant RBs continue to replicate their genomes [57]. Third, these aberrant RBs can resume development and make infectious EB when the persistence inducing stimulus is removed [58].

Many stimuli can induce persistence in vitro. In the following paragraphs the most studied persistence models will be discussed (e.g. penicillin treatment,
iron and amino acid limitation). However, the focus of this dissertation will be on the IFN-γ persistence model.

**Penicillin-induced persistence**

Penicillin was the first stimulus identified that induces *Chlamydia* persistence [48]. Chlamydiae contain 3 PBPs (PBP1, PBP2, and PBP3). PBP1 and PBP2 have transpeptidase activity, while PBP3 has carboxypeptidase activity [59, 60]. When penicillin bind PBPs, RB replication and RB to EB differentiation is inhibited, leading to the formation of enlarged RB. Removal of penicillin allows persistent RB to reactivate and resume normal development [48]. These studies suggest that physically limiting RB division is sufficient to induce persistence. However, limiting available nutrients can also induce persistence, and may be more relevant *in vivo* as penicillin treatment is not routinely used to treat chlamydia.

**Iron limitation induced persistence**

Iron is a key co-factor utilized in both eukaryotic and prokaryotic cellular processes. As obligate intracellular pathogens, chlamydiae are highly dependent on host cells for free iron. The iron chelating agent deferoxamine mesylate (DAM) reduces free iron and induces chlamydiae to enter persistence. Unlike in the penicillin induced persistence model, DAM treatment causes the inclusion to bleb vesicles and alters the morphology of RB and EB. Additionally, some of the chlamydial inclusions have a ruffled membrane and associate with an unknown electron dense material [61].

The phenotypes observed with DAM treatment are not consistent with other chlamydial persistence models. Further investigations revealed DAM does not passively diffuse through cellular membranes, suggesting the phenotypes
elicited by DAM may be caused by inadequate iron-chelation [62]. Consistent with this hypothesis, treatment with 2,2’-bipyridyl (BpdI), a membrane permeable iron chelator, caused *C. trachomatis* to form aberrant RB that resemble those seen in other persistence models [63].

**Amino acid limitation induced persistence**

Depletion of amino acids (AA) can induce *C. trachomatis* persistence. For example, depleting cells of any of the branched chained amino acids (BCAA), isoleucine (Ile), leucine (Leu), or Valine (Val) inhibited *Chlamydia pneumoniae* and *C. trachomatis* EB production [64, 65]. However, depleting cells of a second structurally similar AA partially restored EB production [66]. These results indicate that depletion of one AA can be partially reversed by removal of a second AA, suggesting that the depleted AA is competitively inhibiting the uptake of the second AA, whose unopposed uptake results in persistence.

High concentrations of AA can also induce persistence through competitive inhibition of chlamydial AA transporters. For example, elevated levels of Ile, Leu, phenylalanine (Phe), and methionine (Met) competitively inhibit the transport of Val into *C. trachomatis*. When this occurs, *C. trachomatis* forms small inclusions filled with aberrant RB similar to those seen in other persistence models. However, competitive inhibition is alleviated when cells are co-treated with Val, suggesting Val starvation induces *C. trachomatis* persistence [67].

Co-infection with other intracellular pathogens can also induce *C. trachomatis* persistence. For example, *C. trachomatis* enters persistence when HeLa cells are co-infected with *Toxoplasma gondii*. As *T. gondii* is an intracellular parasite, it likely outcompetes *C. trachomatis* for specific nutrients
such as iron, lipoic acid, cholesterol, and AA, inducing *C. trachomatis* persistence. Consistent with this hypothesis, when pyrimethamine killed *T. gondii*, *C. trachomatis* reactivated from persistence. Additionally, by supplementing the medium with essential AA, *C. trachomatis* was able to reactivate from persistence. These results suggest essential AA limitation was the key factor inducing persistence [68].

**IFN-γ mediated persistence**

The IFN-γ mediated persistence model may be the most relevant model of chlamydial persistence model because this cytokine is essential to controlling *Chlamydia* infections in animals. Moderate concentrations of IFN-γ induces *Chlamydia psittaci* and *C. trachomatis* to enter persistence in T24 and HeLa 229 (HeLa) cells, respectively [58, 69]. IFN-γ treatment causes host cells to upregulate indoleamine 2,3-dioxygenase (IDO1) (Figure 4A), which catabolizes tryptophan (Trp) to N-formylkynurenine (Figure 4B). Additionally, IFN-γ does not induce *C. trachomatis* persistence in IDO1 deficient cells [70], and supplementing the medium with Trp causes persistent RB to reactivate [58, 71]. Furthermore, decreasing the concentration of Trp in the medium in the absence of IFN-γ can also induce *C. trachomatis* persistence [72]. These results indicate that IDO1 mediated Trp starvation is the persistence-inducing stimulus in the IFN-γ mediated persistence model [58, 73].

Urogenital strains of *C. trachomatis* can circumvent Trp starvation because they encode a functional tryptophan synthase (TS), which can synthesize Trp from indole and serine (Ser) (Figure 4C) [74-78]. Neither humans nor *C. trachomatis* synthesizes indole, suggesting that indole is scavenged from
another source, possibly indole-producing microorganisms in the genital and GI tract [79-81].

**Differential gene expression between persistence models**

All persistence inducing stimuli cause chlamydiae to form small inclusions filled with aberrant RB. However, it is unknown what genes mediate this transition. A transcriptomic study indicated many genes are up- or down-regulated in persistent RB, during IFN-\(\gamma\) mediated persistence, as compared to normal RB, growing in the absence of IFN-\(\gamma\). The microarray data indicate that many of the up-regulated genes are involved in tryptophan synthesis, DNA repair, and phospholipid biosynthesis, while many of the down-regulated genes are involved in RB to EB differentiation, cell division, and the TCA cycle [82]. As this is the only transcriptome study focusing on *C. trachomatis* persistence, it is hard to determine if there are common and stimuli specific persistence genes.

Using different persistence inducing stimuli, several studies have examined the differential expression of a few specific genes during chlamydial persistence. Comparing the data from these studies suggests that gene expression varies between different persistence inducing stimuli [83-85]. For example, *ftsK*, an essential cell division gene, is up-regulated in the penicillin induced persistence model, but down-regulated in the IFN-\(\gamma\) mediated persistence model [82, 83]. Additionally, *ftsW*, which encodes a lipid II flippase, remains unchanged in the penicillin model but is down-regulated in the IFN-\(\gamma\) model [37, 86]. In contrast, some genes share the same transcriptomic profile such as *hctB*, a histone-like gene, which is down-regulated in both the penicillin and IFN-\(\gamma\) persistence models. These data suggest that common persistence genes are likely involved with RB to EB differentiation, while stimuli specific
persistence genes may participate in alleviating the persistence inducing triggers.

**In vivo evidence for persistence**

There has been concern that chlamydial persistence is an artifact elicited by *in vitro* stimuli because detecting persistent chlamydial forms in patients has proven challenging. Some challenges include detecting persistent RB forms in tissue and confirming that these are VBNC.

Animal models show the presence of VBNC *Chlamydia in vivo* [87] and that they can be reactivated to produce viable EB [88]. Additionally, VBNC *C. trachomatis* may have also been detected in tubal biopsy specimens. The majority of these samples contained chlamydial DNA and antigens, but *C. trachomatis* could only be cultivated from 3 out of 25 patient samples [89]. Furthermore, persistent RBs have been detected in other patient samples. Aberrant RBs have been observed in fibroblasts and macrophages gathered from the synovial tissue of patients with Reiter’s syndrome [90], as well as macrophages collected from aortic valve tissue [91].

A recent study of cervical scrapings provided some of the best evidence that *C. trachomatis* persistence models may be relevant in humans. Transmission electron microscopy (TEM) of the cervical scrapings revealed multiple inclusions of varying size containing normal RB, EB, and aberrant RB. These samples also contained a high concentration of chlamydial genomes but produced few infectious EBs. Additionally, genital secretions of one patient were assayed and found to contain a high concentration of IFN-γ and indole [92]. These results suggest that *in vivo* conditions exist to induce *C. trachomatis* to enter and reactivate from IFN-γ mediated persistence. However, it remains
unclear if persistence occurs in vivo or is relevant to human disease because of the limited number of patient samples.

Section VI:

Chlamydial genetics

The C. trachomatis serovar D genome indicated it is A+T rich (58.7%), approximately one megabase in size, and encodes approximately 900 functional genes [78]. Comparisons of chlamydial genomes have indicated that they are highly conserved and that relatively few novel genes influence virulence and tropism between organisms. However, most of these genes have not been systematically characterized because the tools required for genetic manipulation of Chlamydia spp. have only been developed in the last few years [76, 93-95].

Genetic manipulation of C. trachomatis

The Wyrick group used electroporation to transform C. trachomatis with a shuttle vector expressing a chloramphenicol acetyltransferase (cat) cassette [96]. However, the shuttle plasmid was not stably maintained. Subsequently, the Maurelli group used electroporation to transform C. psittacci with a mutated 16S rRNA gene that could confer resistance to spectinomycin (Spc) and kasugamycin (Ksm). Recombinants that integrated the foreign DNA were resistant to both Spc and Ksm. This study confirmed that electroporation could deliver linear DNA and that foreign DNA could be integrated into Chlamydia genomes.

Recently, C. trachomatis L2 was transformed with a recombinant shuttle plasmid (pBR325::L2) using CaCl₂. This shuttle plasmid was a fusion of an E. coli plasmid (pBR325) containing a β-lactamase and a cat cassette and an endogenous Chlamydia plasmid, which allowed stable maintenance of the
plasmid in both *E. coli* and *C. trachomatis* [97]. The Clarke group also demonstrated that it was possible to stably express GFP from a shuttle vector (pGFP::SW2) [97]. Stable plasmid transformation of *C. trachomatis* led to the development of new approaches to mutate chromosomal and plasmid genes and express introduced genes in *Chlamydia*.

**Mutagenizing C. trachomatis**

Most *Chlamydia* spp. have a plasmid suggesting that these play vital roles in chlamydial pathogenesis. Systematic interrogation of *C. trachomatis* plasmid genes, using PCR-based deletion mutagenesis and transformation indicated that *pgp1*, *pgp2*, *pgp6*, and *pgp8* are essential for plasmid maintenance [98]. Other plasmid studies confirmed that plasmid genes contributed to virulence [99].

Identification of plasmid maintenance genes permitted the development of a reverse genetic method called fluorescence reported allelic exchange mutagenesis (FRAEM). In this approach, a suicide vector was constructed by modifying the pGFP::SW2 shuttle plasmid. Plasmid stability was regulated by placing *pgp6*, an essential plasmid maintenance gene, under the control of a tetracycline-inducible promoter. In the presence of anhydrotetracycline (ATc), *pgp6* expression increases and the suicide vector is stably maintained. However, in the absence of ATc, *pgp6* expression decreases and the suicide plasmid is lost. To inactivate specific genes by homologous recombination, regions of the chlamydial chromosome surrounding the targeted gene were introduced into the suicide plasmid on either side of a β-lactamase and GFP-expressing gene. Transformants that had homologously recombined out the target gene were enriched for by passaging the recombinants in the absence of ATc and presence of penicillin G [100].
Stable transformation permitted adaptation of other genetic tools for *Chlamydia*. Sigma’s TargeTron Gene Knockout System is a reverse genetic technique that can inactivate specific genes by inserting a group II intron. This approach takes advantage of group II introns’ ability to self-splice from precursor RNAs and form RNA lariats, which can invade genomic DNA targets by reverse splicing. Self-splicing of group II introns is mediated by the intron-encoded protein LtrA, which acts as a DNA binding endonuclease, reverse transcriptase and RNA maturase [101]. In the TargeTron Gene Knockout System, the *ltrA* region of the group II intron is replaced with a selectable antibiotic marker, and *ltrA* is placed on a suicide vector with the modified group II intron.

TargeTron was used to inactivate *C. trachomatis incA*. A modified TargeTron vector, containing a β-lactamase cassette and *incA* targeting sequences, was transformed into *C. trachomatis*. Transformants, which incorporated the modified group II intron, were enriched for by growing them in the presence of penicillin G. Loss of the suicide vector and inactivation of *incA* by the group II intron was confirmed by PCR [102]. TargeTron mediated knockout (KO) of *incA* was the first report of targeted site-directed mutagenesis in *Chlamydia*. Subsequently, the same group developed a similar vector that encodes a Spc resistance cassette, allowing them to construct a double *incA/rsbV1* mutant [103].

Although the new plasmid-based site-directed mutagenesis methods are powerful, their use so far has been is restricted to non-essential genes. In contrast, chemical mutagenesis has been employed in a variety of forward and reverse genetic applications to investigate essential and non-essential genes.
The most frequently used mutagen in the *Chlamydia* literature is ethyl methanesulfonate (EMS) [104, 105], although both N-ethyl-N-nitrosourea (ENU) [106] and nitrosoguanidine (NTG) [107] have also been used. EMS preferentially causes GC to AT transitions and can generate nonsense and missense mutations [108]. A *C. trachomatis* trpB nonsense mutant was isolated by screening pools of EMS mutagenized chlamydiae using a reverse genetic approached called targeted induced local lesions in genomes (TILLING) [109]. Other groups have used EMS mutagenesis to generate mutant libraries for forward genetic screens. Glycogen deficient [110], temperature sensitive [111], and interferon-sensitive [112] mutants have been isolated from EMS mutant libraries in recent studies.

**Recombination and mapping mutant genes**

Chemical mutagens can elicit partial and total loss-of-function mutations in chlamydial genes. A limitation of using chemical mutagens is that the resulting mutants often contain multiple mutations [106], making it difficult to determine which mutated gene causes the phenotype of interest. Sometimes the relevant mutation can be identified by sequencing mutants that have the same phenotype [110].

A more robust method for linking mutations to phenotypes was developed based on observations that *Chlamydia* spp. encode recombination machinery [78], and that clinical *Chlamydia* strains can exchange DNA [77, 113-115]. Demars *et al.* first recapitulated natural chlamydial lateral gene transfer (LGT) *in vitro*. They showed that if cells were co-infected with *C. trachomatis* strains encoding different antibiotic resistance alleles, doubly resistant recombinants could be enriched in the presence of the cognate antibiotics. [116].
Subsequent studies showed that in vitro LGT involves the transfer of large contiguous regions of chlamydial genomes, up to 790 kilobases (kb) [77]. However, the utility of this approach for mutation mapping was limited by the location and scarcity of known endogenous resistance alleles, as well as the fitness costs associated with some of these alleles. The development of counterselection LGT circumvented some of these limitations. In contrast to antibiotic LGT, counterselection LGT enriches for recombinants that have a wild-type phenotype by selecting against mutants that still contain a deleterious mutation [111]. The mutation linked to the phenotype of interest can then be inferred by comparing the mutations in the parent and recombinant mutant strains.

**Identifying critical C. trachomatis persistence genes**

In this study, we sought to expand upon the classical view of chlamydial persistence through the identification of additional genes that induce C. trachomatis to enter into, maintain, and reactivate from IFN-\(\gamma\) mediated persistence. Using newly developed chlamydial genetic tools, we made an EMS mutagenized library and screened for loss-of-function mutants that formed fewer inclusions following reactivation with indole. From the persistence screen, we identified six mutants that were susceptible to IFN-\(\gamma\) mediated persistence (Sip) mutants. We were able to map the persistence alleles in 3 of the Sip mutants using counterselection LGT.

One of the Sip mutants had a mutation in \(trpB\). A mutation in \(trpB\) was expected because TrpB plays a critical role in the synthesis of Trp. However, the other two mapped Sip mutants had mutations in novel persistence genes
**CTL0225** and **CTL0694.** *In silico* analysis of these genes indicate that they might play a role in AA transport and DNA damage repair, respectively.

We used competitive inhibition to test the hypothesis that CTL0225 may transport BCAA (Ile, Leu, and Val), as well as Ser, cysteine (Cys) and alanine (Ala). Additionally, metabolomics analysis comparing uninfected and infected HeLa cells in ± IFN-γ conditions indicated that AA pools might be limiting following IFN-γ treatment. These results suggest that AA transport is critical during IFN-γ mediated persistence, and that *C. trachomatis* utilizes multiple strategies to counteract the effects of host interferon-stimulated genes.
Figure 1. Prevalence of active and suspected regions of trachoma in 2015. Globally endemic trachoma infections are only prevalent in 42 countries with the highest rates of infection occurring in areas that are rural and have poor sanitation. (Trachoma Atlas – Last accessed September 2016)
Figure 2. Sexually transmitted *C. trachomatis* infections in the US. National surveillance data indicate that rates of *C. trachomatis* infection were highest in Washington DC. The majority of the Southern states, such as Louisiana and Mississippi, had a higher incidence of infection than Northern states, such as Washington and New Hampshire (CDC-2014).
Figure 3. *In vitro* *C. trachomatis* L2 life cycle. *C. trachomatis* has a biphasic life cycle alternating between an infectious EB and replicative RB. Following the invasion of a susceptible eukaryotic cell, EB setup a protective niche known as the chlamydial inclusion. The EB then differentiates into an RB and begins to replicate. Following several rounds of replication, some RB asynchronously differentiate back into EB. By 36 hpi, most RBs have differentiated back into EBs. EBs are then released by host cell lysis or extrusion of the inclusion.
Figure 4. IFN-γ mediated persistence. (A) IFN-γ causes the dimerization of the IFN-γ receptor and Janis Kinase 1 and 2 (Jak1/2), which induces the phosphorylation of STAT1. When phosphorylated STAT1 dimerizes and translocates to the nucleus where it binds to GAS elements and upregulates expression of indo1. (B) indo1 encodes the Trp catabolizing enzyme IDO1, which degrades free Trp to N-formylkynurenine. Trp starvation causes C. trachomatis to enter persistence and form aberrant RBs. (C) In response to low levels of Trp, urogenital strains upregulate expression of tryptophan synthase (TrpBA) and can reactivate from persistence by synthesizing Trp from Ser and indole.
CHAPTER II:
RESEARCH GOALS & HYPOTHESIS

Persistent *C. trachomatis* may contribute to the pathogenesis of chlamydial infections and treatment failure. Determining what genes play a critical role in chlamydial persistence is vital to the development of treatments that specifically inhibit persistent *C. trachomatis* and lessen the burden of chlamydia associated inflammation and disease. Transcriptomic analysis indicates persistent *C. trachomatis* RB up- and down-regulate many genes during IFN-γ mediated persistence. However, none of these genes have been characterized except tryptophan synthase.

Our research goal was to identify susceptible to IFN-γ mediated persistence (Sip) mutants and determine what genes play a critical role in *C. trachomatis* entering into, maintaining, or reactivating from IFN-γ mediated persistence. We hypothesize that many of the Sip mutants will contain mutations in genes involved in tryptophan synthesis, DNA damage repair, protein synthesis, and nutrient acquisition.
CHAPTER III:
MATERIALS AND METHODS

Cell culture

McCoy and HeLa cells were obtained from the American Type Culture Collection (ATCC) and were grown in 5% CO₂ humidified incubators at 37°C. Unless otherwise stated, the cells were cultivated in DMEM-high glucose medium supplemented with four mM L-glutamine (Hyclone), 10% Fetal Bovine Serum (FBS; Atlanta Biologicals), sodium pyruvate (Hyclone), 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES; Hyclone) and non-essential amino acids (NEAA; Gibco) (DMEM-10).

Chlamydia Propagation and Purification

*Chlamydia trachomatis* serovar L2 434/Bu (*C. trachomatis* L2) was obtained from the ATCC and propagated in either HeLa or McCoy cells. For infection experiments, *C. trachomatis* L2 EBs were suspended in sucrose-phosphate-glutamic acid buffer (SPG). Flask infections were performed by overlaying the cells with EBs in SPG and rocking the flask for 2 hours at 37°C. Plate infections were carried out by overlaying the cells with EBs in SPG and centrifuging the plate for 1 hour at 1600 x g at room temperature (RT), then rocking the plate for 30 minutes at 37°C. In both cases, the inoculum was then aspirated, and DMEM-10 infection medium was added unless indicated otherwise. When used, purified EBs were prepared by centrifugation over 30% diatrizoic acid (MD-76R) as previously described [26]. Purified and crude EB stocks were stored at -80°C.
Transformation of *C. trachomatis*

*C. trachomatis* L2 was transformed with the pGFP::SW2 plasmid, a kind gift from Dr. Ian Clarke, to produce L2-GFP using a CaCl₂ based protocol with some modifications [97]. Briefly, instead of mixing the transformation mixture with freshly trypsinized McCoy cells, confluent cell monolayers were infected with the transformation inoculum by centrifugation at 250 x g for 1 hour at RT.

**Mutagenesis of L2-GFP**

Confluent monolayers of McCoy cells in T175 flasks were infected with L2-GFP at a multiplicity of infection (MOI) of two (MOI = 2). The medium was aspirated at 18 hours post-infection (hpi), and pre-warmed DMEM-10 + 4 mg/mL ethyl methanesulfonate (EMS) was added. The Flasks were rocked at 37°C for 1 hour, and then the monolayers were washed 3-times with 25 milliliters (mL) of phosphate-buffered saline (PBS). Twenty-five mL of pre-warmed DMEM-10 was added, and then the flasks were incubated for 15 hours. Thirty-four hpi, the medium was aspirated, and sterile SPG and ~ ¼ of an inch of 3 mm beads were added to the flasks. The McCoy cells were detached by manually shaking the flasks. EBs were released from the infected cells by transferring the cell SPG mixture into a 1.5 ml Eppendorf tube containing three 3mm glass beads and then agitating the tube for 2 min at 1600 rpm in an Eppendorf Thermomixer R Shaker Incubator Block Thermo Mixer (bead agitation). Host cell debris was pelleted by centrifuging the resulting cell lysates (250 x g for 10 minutes), and the supernatant containing EBs (mutagenized EB stock) was aliquoted into multiple tubes and frozen at -80°C.

**Mutant isolation, library construction, and library expansion**
L2-GFP mutants were cloned from the mutagenized EB stock using a plaque cloning protocol developed by Matsumoto with a few modifications [117]. Confluent monolayers of McCoy cells in 6-well plates were infected with different doses of the stock to identify an inoculum that yielded 15 to 20 plaques per well. Multiple 6-well plates of McCoy cells were then infected with the same volume of inoculum using replicate aliquots of the mutant EB stock. Four thousand plaques were picked from these plates using a P200 pipet with large orifice low retention pipet tips (Fisher). EBs were released from the plaques by bead agitation in 200 µl SPG and the plaque lysates were arrayed in deep well plates and stored at -80°C. The isolates were expanded by thawing the plaque lysate plates in a 37°C water bath and then using 30 µl of each lysate to infect a McCoy cell monolayer in a 96-well plate. Seventy hpi, the infectious media was aspirated and replaced with SPG (100 µl) and infected monolayers were frozen at -80°C.

Screening for Sensitive to IFN-γ-induced Persistence (Sip) mutants

HeLa cells were seeded in duplicate 96-well plates in DMEM-10. The following day, DMEM-10 was added to one plate (untreated) and DMEM-10 + 10 ng/mL IFN-γ (Thermo Fisher; DMEM-10G) (IFN-γ treated) was added to the other plate. Twenty-four hours later, the monolayers in the two plates were infected with equivalent inocula from the L2-GFP mutant library. The infections were then incubated for 24 hours in DMEM-10 or DMEM-10G. The untreated monolayers were fixed with 3.7% formaldehyde. In contrast, the IFN-γ treated monolayers were rinsed with PBS and tryptophan-free DMEM-10 (UCSF Cell Culture Facility) (DMEM10-TF) + 10 µM indole was added. Twenty-four hours later, these monolayers were fixed in 3.7% formaldehyde (Figure 5). In both
cases, GFP-positive inclusions were imaged using an automatic EVOS™ inverted fluorescent microscope at 4X magnification using a GFP filter set. Inclusions were counted using a custom program developed in FIJI.

**Infectious progeny assays**

HeLa cell monolayers in 24-well plates were infected with various strains. Serial dilutions of the infectious inoculum were used to infect confluent monolayers of HeLa cells in 96-well plates to determine the exact input titer for the progeny assays. At various intervals post infection, the infectious medium was aspirated and replaced with SPG (250 µl) and frozen at -80°C. Infected monolayers were thawed and detached by scraping with a pipet tip (scraping). EBs were released from the thawed cells by bead agitation. Cell debris was pelleted by centrifugation, and EB supernatants were isolated and serially diluted. Serial dilutions were used to infect HeLa cell monolayers in 96-well plates. The infected monolayers were fixed with methanol at 36 hpi. Inclusions were labeled with an anti-chlamydial LPS antibody (EVIH1), a kind gift from Dr. Harlan Caldwell at the National Institutes of Health in Bethesda MD, and a Dylight 488-conjugated anti-mouse IgG. Inclusions were imaged using an automatic EVOS™ inverted fluorescent microscope at 4X magnification using a GFP filter set. Inclusions were counted using a custom macro in FIJI.

**Genome Sequencing**

Confluent monolayers of HeLa cells in 6-well plates were infected with various strains at an MOI = 1. Infected monolayers were detached 36 hpi by scraping with a rubber policeman in SPG, and EB supernatants were prepared using bead-agitation and centrifugation. Host cell DNA was depleted by treating the EB supernatants with RQ1 DNase (Promega) (37 °C, 5% CO₂ for 60 min).
DNase digestion was stopped by adding RQ1 stop buffer to the EB mixture. The EB were then lysed to release their chromosomes by heating the mixture to 65 °C for 10 minutes. Chlamydial DNA was then amplified using a REPLI-g kit (Qiagen), excluding the immunomagnetic cell separation step. Whole genome sequencing (WGS) libraries were prepared from the amplified chlamydial DNA using the NexteraXT DNA Library Preparation Kit. WGS libraries were sequenced at the Center for Genomic Research and Biocomputing Core, Corvallis, OR, on an Illumina HiSeq 2000 to obtain 100 base pair (bp) single-end reads. Genomes were assembled from the resulting reads using Geneious sequencing software version 7, as described previously [118].

**Generating Sip recombinants**

Confluent HeLa cell monolayers in 12-well plates were infected with individual Sip mutants at an MOI = 4, or pairs of Sip mutants each at an MOI of 2. The infected cells were detached 36 hpi by scraping with a rubber policeman in 500 µl SPG and EBs were released from cells by bead agitation and centrifugation.

The persistence screening method (Figure 5) was used to enrich for potential recombinants that had a wild-type phenotype following reactivation with indole. Briefly, EB supernatants were used to infect HeLa cell monolayers in 12 well plates that had been pre-incubated in DMEM-10G for 24 hours to deplete tryptophan. Fresh DMEM-10G was then added, and the infected monolayers were incubated for 24 hours. Infected monolayers were then washed with ice-cold PBS and incubated in DMEM-10TF + 10 µM indole for an additional 24 hours to allow recombinants to reactivate and produce EB. The cells were detached by scraping in SPG, and bead agitation released the EBs. EB supernatants were
isolated by centrifugation and used to initiate another round of infection. This process was repeated until phenotypic revertants that had a wild-type persistence phenotype expanded in individual wells or if no inclusions were observed after five enrichments. The counterselection LGT strategy is outlined in (Figure 6).

**Confirming loss of detrimental persistence allele**

Putative recombinant isolates identified during the co-infections and enrichments in the preceding section were plaque-cloned and expanded. *Chlamydia* DNA was isolated from EBs supernatants of these isolates by adding 50 µl of alkaline lysis buffer to 50 µl supernatant. This mixture was then heated to 95˚C for 10 minutes, and the solution was neutralized by adding 50 µl neutralization buffer. The resulting mixture was used as a template for Sanger sequencing. *Chlamydia* genes of interest were amplified using Phusion™ High Fidelity Polymerase (NEB) and primers listed in Table 1. Cycling conditions recommended by the manufacturer were used, whereas the annealing temperature and extension times were determined by the annealing temperatures of the specific primer pairs and amplicon size, respectively. Primer annealing temperatures were calculated using an online Tm calculator (ThermoFisher). The resulting amplicons were purified using a PCR purification kit (Bio Basic Inc) and sequenced by Eurofins Genomics. The sequences were manually analyzed using the SnapGene Viewer.

**Transmission Electron Microscopy**

Confluent HeLa cell monolayers in 6-well plates were incubated in DMEM-10 or DMEM-10G for 24 hours. These monolayers were infected at an MOI = 0.1 with various strains. The infected monolayers were then treated as described in
the persistence mutant screen (Figure 5). Infected monolayers were fixed with 5% glutaraldehyde and 4% formaldehyde, either 24 hpi, for the untreated plates, or 24 hours post-reactivation (hpr) with indole, for the IFN-\(\gamma\) treated plates. Fixed monolayers were carefully dislodged using a rubber policeman and pelleted in 1.5 mL tubes by centrifugation (250 x g for 10 minutes).

One-percent osmium tetroxide and 1% tannic acid was used to stain the fixed monolayers, which were then dehydrated, and embedded in epoxy resin. Ultrathin sections were made using a Leica ultracut UCT ultramicrotome. Sections were then stained with uranyl acetate and lead citrate. Sections were imaged using a JEOL JEM 1010 microscope with a Gatan 890 4k x 4k digital camera at the Indiana University Electron Microscopy Center in Bloomington, IN.

**Quantitative real-time PCR pre- and post- reactivation**

HeLa cell monolayers were treated using the persistence screening conditions (Figure 5). Monolayers in 6-well plates were infected with the indicated strains at an MOI = 0.1 and collected by scraping in SPG at various hpi. EB supernatants were prepared using bead agitation and centrifugation. DNA was purified from the clarified EB supernatants using a gMAX Mini Kit (IBI Scientific) and was then eluted with elution buffer (10mM Tris-HCl, pH 8.5) as suggested by the manufacturer. One microliter of this template DNA was then mixed with FastStart TaqMan Probe Master mix (Roche), nine pmol of primers (5’-GTAGCGGTAAATGCGTAGA-3’ and 5’-CGCCTTAGCGTCAGGTATAAA-3’), and a probe targeting the *C. trachomatis* 16S rRNA gene, (5’-FAM-ATGTGGAAG/ZEN/AACACCAGT-3’). Quantitative PCR (qPCR) was performed using an Eppendorf Realplex4 device. Standard curves were generated using a known concentration of plasmid that contained a cloned copy of *C. trachomatis*
16S rRNA gene. In both cases, the cycling conditions were: 10 min at 95°C, followed by 40 cycles of 95°C for 20 s, 60°C for 1 min, and 68°C for 20 s.

**Tryptophan-free reactivation assays**

HeLa cells were seeded in 96-well plates in DMEM-10. The following day, the monolayers were rinsed with PBS and then incubated with either DMEM-10 or DMEM-10TF for twenty-four hours. The monolayers were then infected at an MOI = 0.1 with various strains. The infections incubated in DMEM-10 were fixed at 24 hpi, while the infections incubated in DMEM-10TF were rinsed with PBS and incubated for an additional 24 h in DMEM-10TF + 10 μM indole before they were fixed. Inclusions were counted and compared between DMEM-10 and DMEM-10TF + 10 μM indole treated monolayers. Persistence ratios were calculated as described above.

**IFN-γ free indole and tryptophan reactivation assays**

Confluent HeLa cell monolayers in 96-well plates were incubated for 24 h in DMEM-10 or DMEM-10G. The monolayers were then infected with various strains at an MOI = 0.1 and incubated in either DMEM-10 (untreated) or DMEM-10TF (TF). The untreated infections were fixed with 3.7% formaldehyde at 24 hpi, while the TF treated monolayers were washed with PBS and then incubated with DMEM-10TF, supplemented with 10 μM indole or 128 mg/L-tryptophan. These infections were fixed 24 hours later. The numbers of inclusions these strains formed in untreated and TF conditions was used calculate a persistence ratio as described above.

**Cross-sectional area of inclusions**

Infected monolayers were fixed with 3.7% formaldehyde and then permeabilized with 100% methanol. Inclusions were labeled with the anti-
chlamydial LPS antibody EVIH1 and Dylight488-conjugated anti-mouse IgG. Inclusions were then imaged at 20X using the automatic EVOS™ inverted fluorescent microscope. A custom macro was developed in FIJI to determine the area of each inclusion. An image scale bar was used to determine the relative pixel to micrometer distance observed in each picture.

**IFN-γ sensitivity assays**

HeLa cell monolayers in 96-well plates were incubated in DMEM-10G for 24 h. The monolayers were infected with various strains at an MOI = 0.1 then incubated in DMEM-10TF supplemented with 128 mg/L-tryptophan and 10 ng/mL IFN-γ. Infected monolayers were fixed 24 hpi with 3.7% formaldehyde, permeabilized with 100% methanol, and the cross-sectional areas of inclusions were determined as described above.

**AA competitive inhibition screen**

HeLa cells were seeded in 384-well plates and infected at an MOI = 0.5 with Sip2. DMEM-10 was supplemented with single AAs (10 mM) or with the indicated pairs (X 10 mM + Y 10 mM) (Figure 7). The AA solutions were adjusted to pH ~7.0 with 10M HCl or NaOH and were filter sterilized. The infected monolayers were fixed 46-48 hpi with 3.7% formaldehyde. Inclusions were permeabilized, stained and their cross-sectional area was measured as describe above. The effects of select AA was confirmed in a second experiment, performed in triplicate, in which the cross-sectional area of at least 1000 inclusions was determined for each unique assay condition and replicate.

**Dose response amino acid competitive inhibition assays**

Hela cells were seeded in 96-well plates and were infected at an MOI = 0.1 with L2-GFP, Sip2, or rSip2, as described above. Infected monolayers were
treated with DMEM-10 supplemented with the indicated concentrations of AA of Ile, Leu, Val, Ala, Cys, Ser. The infected monolayers were fixed 44-48 hpi with 3.7% formaldehyde, permeabilized with 100% methanol, and stained. Cross-sectional areas of inclusions were measured as describe above.

**Metabolomics assays**

**Infection and collection**

Confluent HeLa cell monolayers in T175 flasks (3 biological replicates for each condition) were incubated in DMEM-10 or DMEM-10G for 24 hours to deplete tryptophan. The media was aspirated (time zero), and different sets of flasks that had been incubated in DMEM-10 or DMEM10 were either mock infected or infected with L2-GFP at an MOI = 0.5. Infected monolayers were harvested from the flasks at various times post infection. The monolayers were washed with ice-cold PBS and cells were detached by treating them with trypsin for five minutes. The cells were then washed with ice-cold PBS and pelleted by centrifugation at 500 x g for 5 minutes at 4°C. The supernatants were discarded, and the cell pellets were weighed and frozen -80°C.

**Processing of cell pellets and QQQ-HPLC Mass Spectrometry**

Cell pellets were thawed on ice and suspended in 100 µl (ddH2O, trichloroacetic acid (TCA) (500 mg/ 350 µl ddH2O) and aminobutyric acid (ABA) (10 ug)). The cell pellet mixture was then vortexed for 30 seconds, and cell debris was pelleted by centrifugation (500 x g for 10 minutes). The supernatant was then transferred to a new tube, and an equal volume of acetonitrile was added. Samples were then stored at -20°C.

Samples and AA standards were thawed on ice and separated on an Intrada AA column using an Agilent 6460 triple quadrupole mass spectrometer.
coupled with the Agilent 1200 Rapid Resolution HPLC. Free AA concentrations (ng) were determined using Agilent software and normalized to pellet weight (ng/mg). Free AA concentrations were compared between the indicated conditions and time points.

**Isolation of suppressor mutants**

Confluent monolayers of HeLa cells in T175 flasks were incubated in DMEM-10G for 24 hours and then infected at an MOI = 10 with various Sip mutants in SPG. The SPG was aspirated, and DMEM-10G was added. Twenty-four hpi, the flasks were washed with ice-cold PBS and then DMEM-10TF + indole was added. Twenty-four hours later, the infected monolayers were lysed using glass beads in SPG and centrifuged to produce EB supernatants. These supernatants were then used to infect fresh flasks of HeLa cells that had been pretreated with IFN-γ. The process mentioned above was repeated until most of the HeLa cells in the flask were infected or if no inclusions were observed after five passages. Putative suppressor mutants were plaque cloned and expanded for further characterization similarly as described above.

**Electroporation of *E. coli* strains**

Mutant and wild-type copies of CTL0225 and CTL0226 were cloned into *E. coli* expression vectors (Table 2). *E. coli* strains were ordered from the *E. coli* genetics stock center at Yale University (Table 3). The strains were made electrocompetent using a protocol from the Dr. Jeffery Barrick’s Lab with some modifications (http://barricklab.org/twiki/bin/view/Lab/ProtocolsElectrocompetentCells). *E. coli* colonies were picked from plates and were then grown overnight in LB + Kanamycin broth (50 µg/mL). Five-hundred microliters of the overnight cultures
were used to inoculate 250 mL of LB broth, and these were incubated shaking at 37°C until an OD_{600} of ~0.6-1.0 was reached. The bacteria were pelleted by centrifugation (3220 x g for 10 minutes) in 50 mL conical tubes. The pellet was then suspended and washed with 30 mL of ice-cold 10% glycerol solution. The centrifugation and washing steps were repeated four times. The cells were then suspended in 500 µl of 10% glycerol and 50 µl aliquots were flash frozen in dry ice and stored at -80°C.

Electrocompetent *E. coli* strains were thawed on ice and transformed with ~70 ng of the desired vector using pre-chilled electroporation cuvettes (BioRad 0.1 cm gap). The transformation mixture was then added to 900 µl pre-warmed SOC media in 15 mL Falcon tubes and incubated for 60 minutes at 37°C with shaking. Fifty microliters were then plated on LB + Amp plates and incubated overnight at 37°C. Transformant colonies were picked to a patch plate and screened for the desired insert by colony PCR.

**Bioinformatic Analysis**

**Transmembrane prediction software TMHMM Server 2.0**

FASTA formatted AA sequences were submitted for analysis to the TMHMM Server 2.0 transmembrane prediction server (http://www.cbs.dtu.dk/services/TMHMM/). Transmembrane domains were graphed using TOPO2 transmembrane protein display software (http://www.sacs.ucsf.edu/TOPO2/).

**Statistics**

Data were analyzed using GraphPad Prism version 6.0 for Windows. Statistics were calculated using One-Way and Two-way ANOVA and Dunnett’s *post hoc* test for multiple comparisons.
Figure 5. IFN-γ persistence screen. HeLa cells were seeded in parallel plates. One plate was treated with IFN-γ while the other plate received fresh DMEM-10. Untreated and IFN-γ treated HeLa cell monolayers were then infected with equal volumes of mutant isolates from an EMS-mutagenized L2-GFP library. Untreated monolayers were fixed at 24 hpi, while the media from IFN-γ treated monolayers was replaced with DMEM-TF supplemented with indole. Persistent chlamydiae were reactivated for 24 hours and then monolayers were fixed. Inclusions from the untreated and IFN-γ treated plates were counted and compared. Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Co-infect HeLa cells with Sip mutants

Persistence Screening Conditions

Pre-treatment  Infect  Reactivate  Harvest

IFN-γ  Lysate  Indole  Lysate

Enrich for recombinants

**Figure 6. Counterselection LGT.** HeLa cells were infected with pairs of Sip mutants (e.g. Sip1 x Sip2). Thirty six hpi, EBs were collected in SPG and then a portion was used to infect HeLa cell monolayers pre-treated with IFN-γ. Twenty four hpi, infected monolayers were washed and treated with DMEM-10TF + 10 μM indole to allow Sip recombinants to reactivate. Twenty four hours post reactivation, the infected monolayers were collected in SPG and the EB supernatants were then used to initiate another round of infection.
Figure 7. AA competitive inhibition screen. HeLa cell monolayers in 384-well plates were infected with Sip2 and treated with the above combinations of AAs at a concentration of 10 mM. Blue boxes indicate wells with large inclusions, red boxes indicate wells that contained small inclusions, and green boxes indicate a combination of AAs that inhibited the formation of small inclusions.
Table 1. Primers used in this study

<table>
<thead>
<tr>
<th>Primer</th>
<th>Gene</th>
<th>Purpose</th>
<th>5' to 3' Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>DN0247</td>
<td>trpA</td>
<td>PCR-Forward</td>
<td>ATCATCCGCAGAAACAGAGG</td>
</tr>
<tr>
<td>DN1593</td>
<td>trpRBA</td>
<td>PCR-Forward</td>
<td>GCTATGCACATTTACTGAAGACTAG</td>
</tr>
<tr>
<td>DN1594</td>
<td>trpB</td>
<td>Mutation confirmation-Reverse</td>
<td>GTCCATCGTCATTTGAAGAGATAC</td>
</tr>
<tr>
<td>DN1595</td>
<td>trpB</td>
<td>Sequencing-Forward</td>
<td>GTATCTTCTTCAAGATGACGATGGAC</td>
</tr>
<tr>
<td>DN1596</td>
<td>trpRBA</td>
<td>PCR-Reverse</td>
<td>GCTCATCAAAGGATATGATTCATG</td>
</tr>
<tr>
<td>DN1597</td>
<td>trpB</td>
<td>Sequencing-Forward</td>
<td>GCTATTGATGCGCCCTAGAGATTTTC</td>
</tr>
<tr>
<td>DN1598</td>
<td>trpB</td>
<td>Sequencing-Reverse</td>
<td>GAAATACCTCTAGGGCCATCAATAG</td>
</tr>
<tr>
<td>DN1599</td>
<td>trpA</td>
<td>Sequencing-Reverse</td>
<td>CCGATACCTTCTACGATCTCTAAG</td>
</tr>
<tr>
<td>DN1621</td>
<td>trpB</td>
<td>Sequencing-Forward</td>
<td>GCATTGGAGTCCTTCACATGC</td>
</tr>
<tr>
<td>DN1622</td>
<td>trpA</td>
<td>Sequencing-Reverse</td>
<td>ACACCTCCTGAATCGAGC</td>
</tr>
<tr>
<td>DN1623</td>
<td>trpR</td>
<td>Sequencing-Forward</td>
<td>AATCAAGAGGAGTCTGGCT</td>
</tr>
<tr>
<td>DN1624</td>
<td>trpR</td>
<td>Sequencing-Reverse</td>
<td>GAGGATCTGATCCTTAAAG</td>
</tr>
<tr>
<td>DN1626</td>
<td>16S rRNA</td>
<td>qRT-PCR-Forward</td>
<td>GGAGAAAAGGGAATTTCAC</td>
</tr>
<tr>
<td>DN1627</td>
<td>16S rRNA</td>
<td>qRT-PCR-Reverse</td>
<td>TCCACATCAAGTAGTACATCG</td>
</tr>
<tr>
<td>DN1639</td>
<td>CTL033</td>
<td>Mutation confirmation-Forward</td>
<td>CACTATGGGATAATAAGGTGATTATCG</td>
</tr>
<tr>
<td>DN1640</td>
<td>CTL033</td>
<td>Mutation confirmation-Reverse</td>
<td>GTCTGACCTTACTCTGATC</td>
</tr>
<tr>
<td>DN1641</td>
<td>CTL0124</td>
<td>Mutation confirmation-Forward</td>
<td>GAAGCGATGGTTAATAGAGAACS</td>
</tr>
<tr>
<td>DN1642</td>
<td>CTL0124</td>
<td>Mutation confirmation-Reverse</td>
<td>CTCCTATAGAAGCTGCTCTAC</td>
</tr>
<tr>
<td>DN1643</td>
<td>CTL0133</td>
<td>Mutation confirmation-Forward</td>
<td>CCACTATGGGCTAATTTATGG</td>
</tr>
<tr>
<td>DN1644</td>
<td>CTL0133</td>
<td>Mutation confirmation-Reverse</td>
<td>CCTAACGCTATTAAGAGACATTG</td>
</tr>
<tr>
<td>DN1645</td>
<td>CTL0209</td>
<td>Mutation confirmation-Forward</td>
<td>GATTTCTTACATATTCCAGTGG</td>
</tr>
<tr>
<td>DN1646</td>
<td>CTL0209</td>
<td>Mutation confirmation-Reverse</td>
<td>CTATAGCTTGAATAATGGCCC</td>
</tr>
<tr>
<td>DN1647</td>
<td>CTL0129</td>
<td>Mutation confirmation-Forward</td>
<td>GCAAGTTTACCTACATCCTGATTAG</td>
</tr>
<tr>
<td>DN1648</td>
<td>CTL0129</td>
<td>Mutation confirmation-Reverse</td>
<td>CCCAGAAACACACCCCAAG</td>
</tr>
<tr>
<td>Primer</td>
<td>Gene</td>
<td>Purpose</td>
<td>5' to 3' Sequence</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>-----------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>DN1649</td>
<td>CTL0225</td>
<td>Mutation confirmation-Forward</td>
<td>GTCGATGTAATCATTGCTGGG</td>
</tr>
<tr>
<td>DN1650</td>
<td>CTL0225</td>
<td>Mutation confirmation-Reverse</td>
<td>CCTTCATGGCTATGTCCTT</td>
</tr>
<tr>
<td>DN1651</td>
<td>CTL0233</td>
<td>Mutation confirmation-Forward</td>
<td>CTACCATAGCTCCTCTTCTACAGG</td>
</tr>
<tr>
<td>DN1652</td>
<td>CTL0233</td>
<td>Mutation confirmation-Reverse</td>
<td>CATCCTGAGTCAGAATCATTCCTATG</td>
</tr>
<tr>
<td>DN1653</td>
<td>CTL0257</td>
<td>Mutation confirmation-Forward</td>
<td>CATGATTGACCATGTTAGG</td>
</tr>
<tr>
<td>DN1654</td>
<td>CTL0257</td>
<td>Mutation confirmation-Reverse</td>
<td>CTTAATTCTAAAGCACTCTTACGATAC</td>
</tr>
<tr>
<td>DN1655</td>
<td>CTL0257</td>
<td>Mutation confirmation-Forward</td>
<td>CCTATCAAGTAGGTGTGAGAG</td>
</tr>
<tr>
<td>DN1656</td>
<td>CTL0325</td>
<td>Mutation confirmation-Reverse</td>
<td>GCCAAATCTAATACCTCAGACTATC</td>
</tr>
<tr>
<td>DN1657</td>
<td>CTL0325</td>
<td>Mutation confirmation-Reverse</td>
<td>CGTCGTTACCAGTATTCTATTACCTATC</td>
</tr>
<tr>
<td>DN1658</td>
<td>CTL0447</td>
<td>Mutation confirmation-Forward</td>
<td>CTATTCTAAAGCACTCTTACGATAC</td>
</tr>
<tr>
<td>DN1659</td>
<td>CTL0447</td>
<td>Mutation confirmation-Reverse</td>
<td>GTATCTAAGCATGGAGGATGATGG</td>
</tr>
<tr>
<td>DN1660</td>
<td>CTL0722</td>
<td>Mutation confirmation-Forward</td>
<td>GTTCGTCAAGTTAGAATTCTTTT</td>
</tr>
<tr>
<td>DN1661</td>
<td>CTL0722</td>
<td>Mutation confirmation-Reverse</td>
<td>GCCTCAAGTAGGTGATTCTTCTTGTAG</td>
</tr>
<tr>
<td>DN1662</td>
<td>CTL0176</td>
<td>Mutation confirmation-Forward</td>
<td>GCAAATCTAATACCTCAGACTATC</td>
</tr>
<tr>
<td>DN1663</td>
<td>CTL0176</td>
<td>Mutation confirmation-Reverse</td>
<td>GCCAAATCTAATACCTCAGACTATC</td>
</tr>
<tr>
<td>DN1664</td>
<td>CTL0566</td>
<td>Mutation confirmation-Forward</td>
<td>GATCTCAATGGAACACTAAACC</td>
</tr>
<tr>
<td>DN1665</td>
<td>CTL0566</td>
<td>Mutation confirmation-Reverse</td>
<td>GCTAGTGAAGGCTCCATACATAC</td>
</tr>
<tr>
<td>DN1666</td>
<td>CTL0354</td>
<td>Mutation confirmation-Forward</td>
<td>GCACCTCAAGTAATAAGATGCATCTC</td>
</tr>
<tr>
<td>DN1667</td>
<td>CTL0354</td>
<td>Mutation confirmation-Reverse</td>
<td>CGCAATGTATCTCTCCTATGAAAC</td>
</tr>
<tr>
<td>DN1668</td>
<td>CTL0366</td>
<td>Mutation confirmation-Forward</td>
<td>CATCAGCTCTATGCTTAAAGC</td>
</tr>
<tr>
<td>DN1669</td>
<td>CTL0366</td>
<td>Mutation confirmation-Forward</td>
<td>GCTTTACCTCACACACATGATAAC</td>
</tr>
<tr>
<td>DN1670</td>
<td>CTL0440</td>
<td>Mutation confirmation-Reverse</td>
<td>CGTCTTGTCAATCTTACGAGAAG</td>
</tr>
<tr>
<td>DN1671</td>
<td>CTL0440</td>
<td>Mutation confirmation-Reverse</td>
<td>GAGAAAATGTAAGTACAAGAATG</td>
</tr>
<tr>
<td>DN1672</td>
<td>CTL0175</td>
<td>Mutation confirmation-Reverse</td>
<td>CTCTTCTAGGATATACTGAGACCTC</td>
</tr>
<tr>
<td>DN1673</td>
<td>CTL0641</td>
<td>Mutation confirmation-Forward</td>
<td>CGATACTCACAAAAACGCATTTC</td>
</tr>
<tr>
<td>DN1674</td>
<td>CTL0641</td>
<td>Mutation confirmation-Reverse</td>
<td>CTTTCTGTATGGGATAGTCAAG</td>
</tr>
<tr>
<td>Primer</td>
<td>Gene</td>
<td>Purpose</td>
<td>5' to 3' Sequence</td>
</tr>
<tr>
<td>--------</td>
<td>------</td>
<td>---------</td>
<td>-------------------</td>
</tr>
<tr>
<td>DN1675</td>
<td>CTL0157</td>
<td>Mutation confirmation-Forward</td>
<td>GAACATTCCGGAGTTCCATGG</td>
</tr>
<tr>
<td>DN1676</td>
<td>CTL0157</td>
<td>Mutation confirmation-Reverse</td>
<td>CTCCACTTTGGTAGACAGGAG</td>
</tr>
<tr>
<td>DN1677</td>
<td>CTL0312</td>
<td>Mutation confirmation-Forward</td>
<td>GTAGAAGCGTGCAAGAG</td>
</tr>
<tr>
<td>DN1678</td>
<td>CTL0312</td>
<td>Mutation confirmation-Reverse</td>
<td>CGATGGGTTATCCAAACGAC</td>
</tr>
<tr>
<td>DN1679</td>
<td>CTL0402</td>
<td>Mutation confirmation-Forward</td>
<td>GCTTACATGGCTTTCTATTG</td>
</tr>
<tr>
<td>DN1680</td>
<td>CTL0402</td>
<td>Mutation confirmation-Reverse</td>
<td>CTTGAGTATAATGAGCTTTGATG</td>
</tr>
<tr>
<td>DN1681</td>
<td>CTL0694</td>
<td>Mutation confirmation-Forward</td>
<td>GAACATGGGAGAAGAGCTT</td>
</tr>
<tr>
<td>DN1682</td>
<td>CTL0694</td>
<td>Mutation confirmation-Reverse</td>
<td>GTAGATATTAAGATCAAGGCT</td>
</tr>
<tr>
<td>DN2100</td>
<td>CTL0694</td>
<td>PCR Gene amplification-Forward</td>
<td>CAAGAGAATAGCGAGGTTCTTC</td>
</tr>
<tr>
<td>DN2101</td>
<td>CTL0694</td>
<td>PCR Gene amplification-Reverse</td>
<td>GAGCGATTGAATATCGTACTC</td>
</tr>
<tr>
<td>DN2102</td>
<td>CTL0225</td>
<td>PCR Gene amplification-Forward</td>
<td>GTAAAGTTCGTAATATGCAAG</td>
</tr>
<tr>
<td>DN2103</td>
<td>CTL0225</td>
<td>Sequencing Forward</td>
<td>CGAATAGTAGCAGCAAGAG</td>
</tr>
<tr>
<td>DN2104</td>
<td>CTL0225</td>
<td>Sequencing Reverse</td>
<td>CCATAGCCTTTCCTTCTCATG</td>
</tr>
<tr>
<td>DN2105</td>
<td>CTL0226</td>
<td>PCR Gene amplification-Reverse</td>
<td>CTATTCTGTTGATTAGGGTTTC</td>
</tr>
<tr>
<td>DN2106</td>
<td>CTL0226</td>
<td>PCR Gene amplification-Reverse</td>
<td>CTATTCTGTTGATTAGGGTTTC</td>
</tr>
<tr>
<td>DN2107</td>
<td>CTL0442</td>
<td>Mutation confirmation-Forward</td>
<td>GGTCTCGATCCCTGAATATAAATAGG</td>
</tr>
<tr>
<td>DN2108</td>
<td>CTL0442</td>
<td>Mutation confirmation-Reverse</td>
<td>GATACGCTTTTTATTAGGATTTAG</td>
</tr>
<tr>
<td>DN2109</td>
<td>CTL0250</td>
<td>Mutation confirmation-Forward</td>
<td>GAATGGCTGAAGATAAGAAC</td>
</tr>
<tr>
<td>DN2110</td>
<td>CTL0250</td>
<td>Mutation confirmation-Reverse</td>
<td>CCTCAATAGTAAACAGTCATC</td>
</tr>
<tr>
<td>DN2111</td>
<td>CTL0252</td>
<td>Mutation confirmation-Forward</td>
<td>GAGCTAGTTTCTGTTTCAGT</td>
</tr>
<tr>
<td>DN2112</td>
<td>CTL0252</td>
<td>Mutation confirmation-Reverse</td>
<td>CAACAGGGACAGTATCAGAAG</td>
</tr>
<tr>
<td>DN2113</td>
<td>CTL0588</td>
<td>Mutation confirmation-Forward</td>
<td>GAAAGAGGACAATTATATGCCTG</td>
</tr>
<tr>
<td>DN2114</td>
<td>CTL0588</td>
<td>Mutation confirmation-Reverse</td>
<td>CCTACAGATCATACTTCTT</td>
</tr>
<tr>
<td>DN2115</td>
<td>CTL0658</td>
<td>Mutation confirmation-Reverse</td>
<td>CCTACAGATCATCATCAGT</td>
</tr>
<tr>
<td>DN2116</td>
<td>CTL0737</td>
<td>Mutation confirmation-Reverse</td>
<td>GAATGGCAGATAAGAAGAAG</td>
</tr>
<tr>
<td>DN2117</td>
<td>CTL0737</td>
<td>Mutation confirmation-Reverse</td>
<td>GAATGGCAGATAAGAAGAAG</td>
</tr>
<tr>
<td>DN2118</td>
<td>CTL0737</td>
<td>Mutation confirmation-Reverse</td>
<td>GAATGGCAGATAAGAAGAAG</td>
</tr>
<tr>
<td>Primer</td>
<td>Gene</td>
<td>Purpose</td>
<td>5' to 3' Sequence</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>---------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>DN2144</td>
<td>trpBA</td>
<td>Cloning pBAD18-EcoRI</td>
<td>GAAAAGGAATTCATGTTCAAACATAAACATCC</td>
</tr>
<tr>
<td>DN2145</td>
<td>trpBA</td>
<td>Cloning pBAD18-HindIII</td>
<td>CATAAAAAGCTTTATCCAGGAATAACTTGTGTGTC</td>
</tr>
<tr>
<td>DN2146</td>
<td>CTL0225</td>
<td>Cloning pBAD18-EcoRI</td>
<td>GTATTIGAATTCATGCTACATTTACTATTTTCGTC</td>
</tr>
<tr>
<td>DN2147</td>
<td>CTL0225</td>
<td>Cloning pBAD18-HindIII</td>
<td>ATTTCCAGCTTTATCTTCTTGACATAGAGAAG</td>
</tr>
<tr>
<td>DN2148</td>
<td>CTL0226</td>
<td>Cloning pBAD18-EcoRI</td>
<td>GCTTCGAAATTCATGGACTGGGTATTATTTTGTTTG</td>
</tr>
<tr>
<td>DN2149</td>
<td>CTL0226</td>
<td>Cloning pBAD18-HindIII</td>
<td>GCTTTCAAGCTTTATAGGAAATTTGTTTAG</td>
</tr>
<tr>
<td>DN2150</td>
<td>CTL0694</td>
<td>Cloning pBAD18-EcoRI</td>
<td>TTAAGAAATTCATGTCTTTATTTCTAAATTCAAGC</td>
</tr>
<tr>
<td>DN2151</td>
<td>CTL0694</td>
<td>Cloning pBAD18-XbaI</td>
<td>TCGGATCTAGATTGATACGTCTGAAACTAGTC</td>
</tr>
</tbody>
</table>

*Bold faced text indicate inserted restriction enzyme site sequence*
Table 2. Plasmids used in this study

<table>
<thead>
<tr>
<th>Plasmid Name</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>pGFP::SW2</td>
<td>C. trachomatis shuttle plasmid</td>
<td>[97]</td>
</tr>
<tr>
<td>pBAD18</td>
<td>Arabinose inducible gene expression cloning vector</td>
<td>This study</td>
</tr>
<tr>
<td>pMM1</td>
<td>pBAD18 expressing wild-type C. trachomatis CTL0225</td>
<td>This study</td>
</tr>
<tr>
<td>pMM2</td>
<td>pBAD18 expressing mutant C. trachomatis CTL0225</td>
<td>This study</td>
</tr>
<tr>
<td>pMM3</td>
<td>pBAD18 expressing wild-type C. trachomatis CTL0226, CTL0225</td>
<td>This study</td>
</tr>
<tr>
<td>pMM4</td>
<td>pBAD18 expressing mutant C. trachomatis CTL0226, CTL0225</td>
<td>This study</td>
</tr>
</tbody>
</table>
Table 3. Bacterial strains used in this study

| Strains     | Description                                      | Source                                                |
|-------------|--------------------------------------------------|                                                      |
| **E. coli** |                                                  |                                                      |
| BW25113     | Parent of JW strains                             | Yale Coli Genetic Stock Center #7636                  |
| JW2767      | Keio collection knockout of serine transporter sdaC | Yale Coli Genetic Stock Center #10170                  |
| JW3060      | Keio collection knockout sstT                    | Yale Coli Genetic Stock Center #10335                  |
| **C. trachomatis** |                                              |                                                      |
| L2-GFP      | L2 434/Bu transformed with pGFP::SW2 plasmid     | This study                                            |
CHAPTER IV:

Isolation and characterization of persistence mutants

Prior comparative transcriptomic studies identified a large number of *C. trachomatis* genes that are differentially expressed in normal and persistent RB [37, 82]. Except for tryptophan synthase (TS) genes, the roles these genes play during IFN-γ mediated persistence have not been explored. Thus, we performed a forward genetic screen to identify genes that are essential for *Chlamydia* to enter into, maintain, and reactivate from IFN-γ mediated persistence.

**Mutant library construction**

A urogenital lymphogranuloma venereum (serovar L2 434/BU) strain that expresses GFP (L2-GFP) was used as the library parent because inclusions of this strain can be visualized directly by GFP fluorescence (Figure 8). L2-GFP was mutagenized with the chemical mutagen ethyl methanesulfonate (EMS). EMS primarily causes GC to AT transition mutations, which can generate both missense and nonsense mutations, but rarely induces insertion and deletion (Indel) mutations [119]. An advantage of using a point mutagen was that it reduced the probability of causing polar effects.

L2-GFP infected McCoy cells were initially treated with EMS to produce a pool of mutant EBs. We observed that high concentrations of EMS substantially decreased chlamydial EB production. However, we were able to recover sufficient numbers of L2-GFP EBs from HeLa cells treated with 4 mg/mL EMS for library construction. EBs were cloned from this mutagenized stock using a plaque assay, and these were then were expanded and arrayed in 96 deep-well plates to make the mutant library.

**Screening for IFN-γ persistence mutants**
We screened a library of 2,016 chemically mutagenized L2-GFP isolates for mutants that had a reduced ability to reactivate from IFN-γ-mediated persistence with indole. Briefly, we infected HeLa cells with the mutant library in ± IFN-γ conditions. We then compared the number of inclusions formed by each isolate in the (−) IFN-γ condition, 24 hours post-infection (hpi), and in the (+) IFN-γ condition, 24 hours post-reactivation (hpr). This comparison led us to calculate a mutant persistence ratio. Mutant and L2-GFP persistence ratios were then compared to normalize for differing MOIs. Similar to previous studies, we observed that L2-GFP produced approximately 50% fewer inclusions following reactivation from IFN-γ mediated persistence than in untreated cells (data not shown) [74, 82]. In contrast, some library isolates formed markedly fewer inclusions following reactivation than in the untreated cells. We identified six persistence mutants from the primary screen and verified that their persistence phenotypes were statistically significant ($p < 0.0001$) in subsequent assays (Figure 9). We named these isolates Sip mutants because they were sensitive to IFN-γ-mediated persistence.

One-step growth curve analysis was used to compare the developmental kinetics of L2-GFP and these six Sip mutants during normal growth conditions. Untreated HeLa cells were infected with L2-GFP and each of the Sip mutants in parallel. The numbers of EBs generated by each Sip mutant were indistinguishable from the number produced by L2-GFP (Figure 10). These results indicated that the Sip mutants were not compromised in fitness and that the mutant persistence phenotypes we observed were related to their inability to enter, maintain, and be reactivated from, IFN-γ mediated persistence.

**Mapping deleterious persistence alleles in the Sip mutants**
A whole-genome sequencing (WGS) approach was used to compare the genomic sequences of L2-GFP and the Sip mutants. Sip mutants had between 2 to 8 mutations and contained at least two nonsynonymous mutations in predicted coding sequences (Table 4).

The lack of overlapping polymorphisms prevented us from using linkage analysis to map the deleterious persistence mutations in the Sip mutants. However, Sip1 had a missense mutation in \(trpB\), which encodes the \(\beta\)-subunit of TS. A mutation in a TS related gene was expected and is a key datum that validates the efficacy of the screen we developed. However, because Sip1 contains two other missense mutations we could not definitively conclude that the mutation in \(trpB\) was causing Sip1 to form fewer inclusions following reactivation from persistence. Thus, we needed a way to link the persistence phenotype to a specific genotype.

We initially used an \textit{in vitro} antibiotic lateral gene transfer (LGT) approach to isolate Sip recombinants and map the deleterious persistence alleles in each strain. Antibiotic LGT enriches for recombinants by selecting against strains that only have one endogenous resistance allele [110, 116]. A limitation of this approach is that endogenous antibiotic resistance alleles acquired by mutating genes such as \(rpoB\), \(gyrA\), and 16S rRNA are known to affect growth [120-124]. Unfortunately, the antibiotic-resistant Sip and recombinant mutant strains we generated had growth defects that confounded attempts to map persistence alleles.

We next sought to map causative persistence mutations by using a counterselection LGT approach. This technique produces markerless recombinants by enriching for strains that have a wild-type phenotype and
selecting against strains that still retain a deleterious persistence allele [111, 112]. As a proof of concept for this mapping strategy, we focused on the Sip mutants that had the strongest persistence phenotypes (Sip1, Sip2, and Sip6).

HeLa cells were co-infected with different pairs of Sip mutants (Sip1 x Sip2, Sip1 x Sip6, Sip2 x Sip6). Co-infections were then repeatedly passaged in HeLa cells cultivated in the persistence screen conditions (Figure 6). Phenotypic revertants arose from these co-infection experiments. In contrast, no revertants arose from control infections that used twice the amount of infectious inoculum of single Sip mutants after several passages. This observation suggested that the phenotypic revertants detected in co-infected wells resulted from recombination and were not genetic revertants or suppressor mutants.

We next attempted to use counterselection LGT to map the other Sip mutants. However, we were unable to enrich for recombinants using the attempted crossing strategy (Sip3 x Sip4, Sip3 x Sip5, and Sip4 X Sip5) because almost every HeLa cell was infected in the co-infected and Sip parent alone wells after the first passage using the persistence screen conditions. This trend continued for several passages. This observation indicated that EB production might influence the ease of enriching for recombinants. To address this hypothesis, we investigated how much infectious EB each of the Sip mutants produced following reactivation from persistence with indole.

Infectious progeny assays were used to compare Sip mutant EB production following IFN-γ treatment and reactivation with indole. Sip1, Sip2, and Sip6 produced the fewest infectious EB as compared to L2-GFP (<5%). In contrast, the decline in EB production of Sip 3, Sip4 and Sip5 was relatively modest (19%, 40%, and 39%, respectively) (Figure 11). These data suggest that
enriching for recombinants is more efficient when Sip mutants produce little to no infectious EB after reactivating from persistence. Since we were unable to map the persistence alleles in Sip3, Sip4, and Sip5, all subsequent assays focus on characterizing Sip1, Sip2, and Sip6.

**Allele mapping uncovers novel persistence genes**

L2-GFP and recombinant Sip (rSip) strains (rSip1, rSip2, and rSip6) formed similar numbers of inclusions after reactivation with indole (Figure 12). Sanger sequencing confirmed that each rSip strain differed from a Sip mutant parent by one nonsynonymous mutation. This analysis linked nonsynonymous mutations in genes encoding the β-subunit of TS (trpB), a putative integral membrane protein (CTL0225), and a putative oxidoreductase (CTL0694) to the persistence phenotypes of Sip1, Sip2, and Sip6, respectively (Table 4).

**Sip mutants fail to reactivate from persistence**

Results from our secondary screen could not be used to determine whether the Sip mutants were compromised in their ability to enter, maintain, or be reactivated from, IFN-γ mediated persistence. To address this issue, we used established methods to examine the inclusions of each mutant. Light microscopy indicated the inclusions of the Sip mutants were significantly smaller ($p <0.0001$) than those of L2-GFP following reactivation, despite being similar or larger in size under normal growth conditions (Figure 13 B-C). TEM revealed that there were no obvious differences in EB or RB morphology in untreated HeLa cells (Figure 14 A-D), consistent with the results of the one-step growth curve experiments (Figure 10). However, in IFN-γ + indole treated HeLa cells, only Sip mutant inclusions still contained aberrant RB following reactivation. In contrast, dividing RB were frequently observed in HeLa cells.
infected with L2-GFP, and rSip strains (Figure 14E-H). These results suggested that the Sip mutants could enter persistence, but could not reactivate from persistence.

Since the results from the TEM analysis indicated that the Sip mutants could not reactivate from IFN-γ mediated persistence, we wanted to test if the remaining inclusions produced infectious EB. Untreated HeLa cells were infected with lysates from IFN-γ-plus-indole-treated infections and inclusions were counted 34 hpi. All three of the Sip mutant strains produced significantly ($p < 0.0001$) fewer infectious EBs than L2-GFP (Figure 15A). This result confirmed that the Sip mutants do not reactivate from persistence with indole and are impaired in their ability to produce infectious progeny.

Additionally, we tested if the Sip mutants produced infectious EBs following reactivation with Trp to determine if Sip2 and Sip6 had defects in acquiring or converting indole into Trp. Trp and indole similarly rescued L2-GFP EB production. In contrast, Trp did not enhance EB production of the any of the Sip mutants ($p < 0.0001$) (Figure 15B). Interestingly, Sip1 EB production was not fully rescued by treatment with Trp ($p < 0.0001$), which was surprising because EB production of a C. trachomatis trpB null mutant can be reactivated with Trp [109]. These results suggest that the reason the Sip mutants are unable to reactivate from persistence is unrelated to Trp availability and that mutant TrpB (TrpB<sup>p221s</sup>) in Sip1 may have a deleterious alternative function.

**Sip1 and Sip2 make fewer genomes following reactivation with indole and tryptophan**

Next, we wondered why the Sip mutants failed to reactivate from persistence with Trp. One possibility was they were dying during persistence. If
the Sip mutants were dying during persistence, then they should have reduced genome replication following reactivation from persistence. Using quantitative PCR (qPCR), we measured and compared the rate at which L2-GFP and the Sip mutants replicated their genomes during IFN-γ treatment and reactivation from persistence with indole and tryptophan.

Consistent with previous reports that *C. trachomatis* genome replication continues during persistence, albeit more slowly [57], L2-GFP and the Sip mutants replicated their genomes slowly between 2 to 24 hpi in IFN-γ treated HeLa cells (Figure 16). However, Sip1 genome replication diverged during reactivation with indole and Trp. Genome replication of Sip1 slightly increased 36 hpr with indole but increased approximately 5-fold during the same interval after the addition of Trp. This result suggested that Trp, but not indole, was able to mitigate the deleterious effects of mutant TrpB (TrpB<sup>221S</sup>) expressed in Sip1. Genome replication of Sip2 was decreased and delayed during reactivation with indole and Trp, suggesting that this mutant might be dying during persistence and is unable to resume rapid replication of its genome. In contrast, Sip6 genome replication was similar to L2-GFP following reactivation with both indole and Trp. These data indicate that Sip6 can survive during persistence, but is unable to transition back into normal RB and EB, while both Sip1 and Sip2 may be dying during persistence due to an unknown mechanism.

**Sip mutants are differentially sensitive to IFN-γ**

IFN-γ upregulates the expression of many ISGs [125]. We tested if IFN-γ treatment could inhibit the development of the Sip mutants in Trp replete conditions, as it could indicate if ISGs are playing a role in Sip1 and Sip2 dying during persistence. Untreated and IFN-γ treated HeLa cells were infected with L2-
GFP and the Sip mutants in parallel. IFN-γ-plus-Trp was added immediately following infection to prevent *C. trachomatis* from entering persistence. The numbers of inclusions formed (Figure 17A) and their relative sizes (Figure 17B) were assessed 24 hpi. Sip1 produced more inclusions (*p* < 0.01) that were not significantly different in size than L2-GFP in the Trp-replete conditions. This result suggested that TrpB<sup>Y221S</sup> expression in Sip1 was only detrimental to chlamydial survival during IFN-γ mediated persistence. Sip2 also formed slightly more inclusions (*p* < 0.05), which were significantly larger (*p* < 0.0001) than those seen with L2-GFP in IFN-γ-plus-tryptophan-treated cells. This result is consistent with the Sip2 inclusions being significantly (*p* < 0.0001) larger than L2-GFP inclusions under normal growth conditions (Figure 13B). In contrast, the numbers of inclusions Sip6 formed were similar to L2-GFP (n.s), but Sip6 formed significantly smaller inclusions (*p* < 0.0001). This result indicated that a Trp-independent effect of IFN-γ might affect the development and subsequent size of Sip6 inclusions during persistence.

**Trp starvation alone prevents Sip mutants from reactivating**

Next, we used a Trp-limiting (TL) persistence model to determine if Trp starvation alone was sufficient to inhibit the Sip mutants from reactivating from persistence with either indole or Trp [72]. We incubated HeLa cells in Trp-free medium (DMEM-10TF) for 24 hours to deplete Trp. Trp-replete and Trp-depleted HeLa cell monolayers were then infected with L2-GFP, Sip and rSip strains. We then compared the number of inclusions formed in Trp-replete conditions, 24 hpi, to the number of inclusions formed in the Trp-deleted conditions, 24 hpr, with indole or Trp. L2-GFP, Sip, and rSip strains formed similar ratios of inclusions following reactivation with either indole or tryptophan (Figure 18).
The ratios calculated from the TF persistence model were similar to ratios observed in the IFN-γ mediate persistence model (Figure 9). These results suggest that Trp limitation alone is sufficient to inhibit the Sip mutants from reactivating from persistence. Additionally, these results indicate Trp starvation was responsible for the phenotypes observed with the Sip mutants in the IFN-γ mediated persistence model.

**The P221S mutation may disrupt substrate channeling of indole and Trp synthesis**

Indole is usually shuttled through a substrate tunnel to the active site of the β-subunit where it interacts with Ser to form Trp. However, in the absence of indole, the β-subunit of TS hydrolyzes Ser into pyruvate and ammonia [126]. We hypothesized that the P221S mutation in Sip1 disrupts indole from interacting with the active site of the β-subunit leading to the production of ammonia instead of Trp. If ammonia is being produced while Sip1 is in persistence, then this could explain why Sip1 does not fully reactivate from persistence with Trp.

Using Phyre2 and PyMOL analysis, we mapped the P221S mutation in TrpB onto the crystal structure of *Salmonella typhimurium* TS. Results from this *in silico* analysis suggested that the P221S mutation was located on the periphery of TrpB and did not directly interact with the substrate tunnel or the active site of the β-subunit. This observation suggests that the P221S mutation must cause a conformational change that disrupts indole from reaching the active site of TrpB^{P221S} (Figure 19).

To gain a better understanding of the P221S mutation and how it may lead to the production of ammonia we generated suppressor mutants. HeLa cells were infected with Sip1, which was then induced to enter and reactivate
from IFN-γ mediated persistence with indole. After several passages, suppressor mutants were isolated, and trpB was Sanger sequenced to determine the location of the suppressor mutation. One of these suppressor mutants had a Q52P mutation, also, located on the periphery of TrpBP221S (Figure 19). This result suggested that the Q52P mutation likely corrects the conformational change that prevented indole from interacting with the active site of the β-subunit.

**CTL0694 may be involved in DNA damage repair**

CTL0694 is annotated as a putative oxidoreductase [78]. Blastp analysis indicated that CTL0694 shares strong protein homology (47%) with an oxidoreductase in *Bacteroides fragilis* whose function is unknown. Other proteins that are similar to CTL0694 are annotated as being part of the sulfite reduction pathway, specifically the α-subunit of the sulfite reductase complex, CysJ.

*E. coli* CysJ shares 28% protein homology to CTL0694. CysJ transfers reducing elections to effector proteins in both the sulfite reduction and a DNA damage repair pathways. In the sulfite reduction pathway, CysJ helps to reduce sulfite to hydrogen sulfide by forming a multimeric complex with CysI (CysJ6CysI4), through its FMN domain. In a DNA damage repair pathway, CysJ forms a complex with YcbX (CysJYcbX) and helps to detoxify mutagenic nucleobases such as HAP to adenine. As CTL0694 lacks an FMN domain, we hypothesize CTL0694 is likely playing a role in DNA damage repair during IFN-γ mediated persistence.

Using PyMOL analysis, we aligned mutant CTL0694 (CTL0694P105L) to *E. coli* CysJ, which revealed that the P105L mutation is close to an FAD-binding site (Figure 20). This observation suggests that the P105L mutation may interfere
with FAD binding to CTL0694. To determine if this was the case, we generated Sip6 suppressor mutants as described above. We isolated a suppressor mutant that encoded a G75S mutation mapped to the periphery of CysJ, far from the FAD binding site (Figure 20). This result indicated that the P105L mutation likely does not disrupt FAD binding but may affect CTL0694 from binding to an effector protein.
Figure 8. *C. trachomatis* L2 was transformed with pGFP::SW2. GFP expression (Green) and anti-chlamydial LPS Alexa 594 staining (Red) was compared 36 hpi. The pattern of GFP expression was similar to that of chlamydial LPS staining.
Figure 9. Secondary screening confirmed that the Sip mutants made fewer inclusions following reactivation as compared to untreated wells and L2-GFP. Bars represent the mean untreated/IFN-γ treated inclusion ratios normalized to L2-GFP. n=3. Error bars indicate SD, ***, p <0.001, ****, p <.0001. Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 10. **Sip mutants exhibit normal growth kinetics.** The number of infectious EB produced by L2-GFP and Sip mutants was assessed at various intervals post infection. The number of inclusions formed for each strain was normalized to the initial inoculum. Data points represent the mean number of infectious progeny obtained from the indicated time points. n=3. Error bars indicate SD.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 11. Sip mutants make fewer EB following reactivation. Cell lysates for L2-GFP and Sip mutants were harvested following reactivation with indole. Infectious EB was enumerated using an infectious progeny assay. Bars represent the mean percentage normalized to L2-GFP. n=3.
Figure 12. Sip recombinants form similar numbers of inclusions as L2-GFP. Sip mutant recombinants isolated from counter-selection LGT, make similar numbers of inclusions as L2-GFP following reactivation from IFN-γ mediated persistence. Bars represent the mean percentage normalized to L2-GFP. n=3, Error bars indicate SD. n.s, non-significant.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 13. Sip mutants make smaller inclusions following reactivation. (A) Fluorescent images of inclusions under normal growth conditions and following reactivation from IFN-γ mediated persistence with indole. (B-C) Quantification of the size of inclusions depicted in (A). > 1000 inclusions were measured. Bars represent the mean percentage normalized to L2-GFP. Error bars indicate SD. ****, \( p < .0001 \), n.s, non-significant.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 14. Transmission electron microscopy of L2-GFP and Sip mutants. (A-D) L2-GFP and Sip mutants form normal sized inclusions and RB in untreated HeLa cells 24hpi. (E-H) Only Sip mutants form small inclusions containing aberrant RB following reactivation with indole from IFN-γ mediated persistence. White arrows indicate examples of aberrant RB.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 15. Sip mutant EB production cannot be rescued by Trp or indole. IFN-γ treated HeLa cells were infected with L2-GFP or Sip mutants and then the infections were reactivated with (A) indole or (B) tryptophan. The infections were harvested 24 h post-reactivation and the EBs in the lysates enumerated in untreated HeLa cells. The number of inclusions each strain formed were normalized to the inoculum and then compared to L2-GFP. The graph depicts the mean of the results of three experiments performed in triplicate. The error bars indicate SD. ****, p < .0001.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 16. Genome replication is altered during Sip mutant reactivation. Genome copy numbers of L2-GFP and the Sip mutants were characterized pre- and post- (A) indole or (B) Trp reactivation using primers and a probe-set targeting the C. trachomatis 16S rRNA gene. The arrows indicate the time of indole or Trp addition. Data points represent the mean number of genome copies from two experiments performed in duplicate.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 17. Sip 6 forms small inclusions in the presence of IFN-γ + Trp (A) The Sip mutants form similar numbers of inclusions in the presence of IFN-γ and excess Trp when compared to L2-GFP. (B) However, only Sip6 makes significantly smaller inclusions. Bars represent the mean percentage normalized to L2-GFP for the number of inclusions, and inclusion area. n=3. At least 1000 inclusions for each strain were analyzed for area of inclusion studies. Error bars indicate SD. *, p <.05, **, p <.01, ****, p <.0001, n.s, non-significant.

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
Figure 18. Trp starvation alone induces Sip mutants to enter persistence HeLa cells were depleted of Trp and infected with the indicated strains. The number of inclusions produced by each strain was compared to L2-GFP following reactivation with either indole or Trp. Bars represent the mean percentage normalized to L2-GFP. n=3. Error bars indicate SD.
Figure 19. Sip1 TrpBP221S aligned to Salmonella typhimurium TS. The mesh crystal structures of the α- and β- subunits of S. typhimurium TS are outlined in cyan and green, respectively. The purple spheres outline a bound substrate threaded through the substrate tunnel connecting the active sites of the α- and β- subunits. The yellow spheres represent pyridoxal 5’-phosphate in the active site of the β subunit. The red spheres outline the location of the P221S mutation in TrpB\textsuperscript{P221S}, and the green spheres indicate the location of the G52P suppressor mutation in Sip1. This image was generated using the PyMOL molecular graphics system.
Figure 20. Sip6 CTL0694\textsuperscript{P105L} aligned to the crystal structure of \textit{E. coli} CysJ. The ribbon model outlines CTL0694\textsuperscript{P105L} and CysJ in green and cyan, respectively. The blue spheres depict the location of a NAD binding site. The red spheres indicate the location of FAD binding sites with bound FAD, which is shown as yellow spheres. Orange and white spheres outline the location of the P105L mutation in CTL0694 and the G75S suppressor mutation in Sip6, respectively. This image was generated using the PyMOL molecular graphics system.
<table>
<thead>
<tr>
<th>Mutant</th>
<th>AA</th>
<th>Codon</th>
<th>Gene</th>
<th>Locus</th>
<th>Expected Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sip1</td>
<td>A -&gt; T</td>
<td>241</td>
<td>groEL</td>
<td>CTL0133</td>
<td>Hypothetical protein</td>
</tr>
<tr>
<td></td>
<td>D -&gt; N</td>
<td>62</td>
<td></td>
<td>CTL0209</td>
<td>Hypothetical protein</td>
</tr>
<tr>
<td></td>
<td>P -&gt; S</td>
<td>221</td>
<td>trpB</td>
<td>CTL0423</td>
<td>Tryptophan synthase subunit beta</td>
</tr>
<tr>
<td></td>
<td>G -&gt; R</td>
<td>298</td>
<td>ftsW</td>
<td>CTL0129</td>
<td>Cell division protein</td>
</tr>
<tr>
<td></td>
<td>G -&gt; E</td>
<td>77</td>
<td></td>
<td>CTL0225</td>
<td>Putative integral membrane protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>258</td>
<td>cpa</td>
<td>CTL0233</td>
<td>Putative exported protease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>93</td>
<td>gatC</td>
<td>CTL0257</td>
<td>Aspartyl/glutamyl-tRNA amidotransferase subunit C</td>
</tr>
<tr>
<td></td>
<td>S -&gt; F</td>
<td>365</td>
<td></td>
<td>CTL0325</td>
<td>ABC transporter permease</td>
</tr>
<tr>
<td></td>
<td>Intergenic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>G -&gt; E</td>
<td>299</td>
<td></td>
<td>CTL0447</td>
<td>Putative integral membrane protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64</td>
<td>ispD</td>
<td>CTL0722</td>
<td>2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sip2</td>
<td>S -&gt; N</td>
<td>246</td>
<td>plsB</td>
<td>CTL0176</td>
<td>Glycerol-3-phosphate acyltransferase</td>
</tr>
<tr>
<td></td>
<td>Intergenic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P -&gt; L</td>
<td>1,128</td>
<td>rpoC</td>
<td>CTL0566</td>
<td>DNA-directed RNA polymerase subunit beta'</td>
</tr>
<tr>
<td>Sip3</td>
<td>G -&gt; R</td>
<td>37</td>
<td>trxB</td>
<td>CTL0354</td>
<td>Thioredoxin reductase</td>
</tr>
<tr>
<td></td>
<td>G -&gt; R</td>
<td>14</td>
<td>groES</td>
<td>CTL0366</td>
<td>Co-chaperonin GroES</td>
</tr>
<tr>
<td></td>
<td>G -&gt; E</td>
<td>39</td>
<td>tmk</td>
<td>CTL0440</td>
<td>Thymidylate kinase</td>
</tr>
<tr>
<td>Sip4</td>
<td>P -&gt; S</td>
<td>831</td>
<td>ptr</td>
<td>CTL0175</td>
<td>Exported insulinase/protease</td>
</tr>
<tr>
<td></td>
<td>H -&gt; Y</td>
<td>37</td>
<td></td>
<td>CTL0641</td>
<td>Hypothetical protein</td>
</tr>
<tr>
<td>Sip5</td>
<td>S -&gt; F</td>
<td>71</td>
<td></td>
<td>CTL0157</td>
<td>Putative integral membrane protein</td>
</tr>
<tr>
<td></td>
<td></td>
<td>39</td>
<td>pmpG</td>
<td>CTL0250</td>
<td>Polymorphic outer membrane protein</td>
</tr>
</tbody>
</table>

Table 4. Mutations in Sip mutants.
<table>
<thead>
<tr>
<th>Mutant</th>
<th>AA</th>
<th>Codon</th>
<th>Gene</th>
<th>Locus</th>
<th>Expected Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sip6</td>
<td>P -&gt; S</td>
<td>225</td>
<td>CTL0312</td>
<td>Hypothetical protein</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>381</td>
<td>nusA</td>
<td>CTL0352</td>
<td>Transcription elongation factor NusA</td>
</tr>
<tr>
<td></td>
<td>D -&gt; N</td>
<td>945</td>
<td>CTL0402</td>
<td>Putative integral membrane protein</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>238</td>
<td>gltT</td>
<td>CTL0658</td>
<td>Sodium:dicarboxylate symport protein</td>
</tr>
<tr>
<td></td>
<td>P -&gt; L</td>
<td>105</td>
<td>CTL0694*</td>
<td>Putative oxidoreductase</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>296</td>
<td>CTL0737</td>
<td>Hypothetical protein</td>
<td></td>
</tr>
<tr>
<td>L2-GFP SNP</td>
<td>R -&gt; C</td>
<td>131</td>
<td>CTL0882</td>
<td>Hypothetical protein</td>
<td></td>
</tr>
</tbody>
</table>

*Mapped persistence allele*

Copyright © American Society for Microbiology, [Infection and Immunity, 84, 2016, 2791-2801, and 10.1128/IAI.00356-16]
CHAPTER V:

Characterization of Sip2

The G77E mutation in CTL0225 may disrupt AA transport

BLASTp identified CTL0225 as a putative integral membrane protein that is highly conserved among *Chlamydia* species (>89%) that is homologous to other intracellular and extracellular bacterial proteins in *E. coli* (31%), *B. aphidicola* (33%), and *C. burnetii* (35%). Additionally, CTL0225 shares homology with a small neutral AA transporter (SnatA) from *Thermococcus* strain KS-1 (29%).

SnatA is predicted to have six transmembrane domains and has been shown to transport glycine (Gly) and alanine (Ala) [127]. Similar to SnatA, THMHMM server 2.0 analysis indicated CTL0225 also contains six transmembrane domains (Figure 21A). Additionally, results from this *in silico* analysis suggested that the Gly77 to glutamate (G77E) mutation in Sip2 disrupts the 3rd transmembrane domain of CTL0225 (Figure 21B). This disruption may occur because Gly77 is located one AA away from a GXXXG motif, which is hypothesized to mediate helix-helix association and proper folding of integral membrane proteins [128]. Collectively, these observations suggest that CTL0225 is an AA transporter and that mutant CTL0225 (CTL0225G77E) is nonfunctional.

Amino acid competitive inhibition causes Sip2 to form small inclusions.

Typically, similar AAs are transported through the same AA transporters [129-131]. However, when one AA is present in excess, AA transport can be inhibited due to competitive inhibition. Braun *et al.* suggested that *C. trachomatis* formed small inclusions in the presence of excess Leu, Ile, Met, and Phe because these AAs are antagonists of Val. They speculated that these AAs
competitively inhibited the transport of Val, which led to a shortage of Val inside *Chlamydia* [67].

We speculated that CTL0225 transports a specific group of AAs and that the G77E mutation in Sip2 makes CTL0225 nonfunctional. Additionally, we hypothesized that Sip2 will form small inclusions in the presence of excess AA that CTL0225 normally transports, due to increased competitive inhibition of other chlamydial AA transporters. To test this hypothesis, we devised an AA competitive inhibition screen where Sip2 infected HeLa cells were treated with a high concentration (10 mM) of 18 single AAs alone or in the indicated pairs (Figure 7). Tyrosine (Tyr) or Trp could not be assessed because high concentrations were either insoluble or cytotoxic, respectively (data not shown).

Sip2 formed small inclusions in cells treated with excess Ile, Leu, Ser, and cysteine (Cys). Small inclusions were not detected in cells co-treated with Val + Ile and Leu or for Ala + Ser and Cys (Figure 7). These results confirm the observation made by Braun *et al.* that high concentrations of Ile and Leu cause Val starvation, and indicate Ser and Cys antagonize the transport of Ala. Additionally, these results indicate that CTL0225 may be playing a role in two different AA transport systems, as these AAs have not been previously described to be transported together.

**Sip2 is hypersensitive to excess isoleucine**

The competitive inhibition screen indicated that Sip2 formed small inclusions in response to treatment with 10 mM Ile. However, it did not differentiate if the small inclusions observed were a normal *C. trachomatis* response to 10 mM Ile. Inclusion sizes of strains encoding a wild-type allele of CTL0225 (L2-GFP, Sip1, Sip6, rSip2) were compared to Sip2 in the presence of
increasing concentrations of Ile (0-30 mM). In the absence of Ile, all strains formed similar sized inclusions. However, when treated with 10 mM Ile, only Sip2 formed significantly smaller inclusions ($p < 0.0001$). This trend continued even at the highest dose (30 mM) assayed ($p < 0.0001$) (Figure 22).

**Excess isoleucine starves Sip2 of valine**

Some AA transporters can transport Ile, Leu, and Val [132-134]. However, the AA competitive inhibition screen indicated that only excess Ile antagonized the transport of Val and not Leu. To confirm our screening results, HeLa cells were infected with L2-GFP, Sip1, Sip2, Sip6, or rSip2 in the presence of 10 mM Ile and increasing concentrations (0-30 mM) of Val or Leu. Results from the competitive inhibition assays indicated that 5 mM Val was sufficient to allow Sip2 to form large inclusions in the presence of Ile (Figure 23A). However, even at the highest concentration of Leu assayed (30 mM), Sip2 did not form large inclusions (Figure 23B). These results indicate that 10 mM Ile starves Sip2 of Val and not Leu. Additionally, these results suggest that when Sip2 is treated with Ile, antagonism of Val transport increases due to the inability of CTL0225G77E to transport Ile.

**Excess cysteine or serine starve Sip2 of alanine**

The competitive inhibition screen indicated that Sip2 was sensitive to high concentrations of Ser and Cys. Using similar competitive inhibition assays as described above with Ile, we validated that treatment with 10 mM Ser (Figure 24) and Cys (Figure 25) caused Sip2 to form significantly smaller inclusions than L2-GFP ($P<0.0001$) 44-48 hpi. Additionally, we confirmed that when Sip2 was co-treated with 10 mM Ser or Cys + Ala, Sip2 formed large inclusions that were similar in size to L2-GFP (Figure 24 and 25). Interestingly, two distinct
populations of inclusions were evident when Sip2 was treated with 10 mM Ser. Most the Sip2 inclusions assayed, following treatment with Ser, were small; however, a minority of inclusions formed a distinct cluster of large inclusions. This phenomenon was only observed when Sip2 inclusions treated with Ser, as treatment with Cys, Ile, or Leu induce Sip2 to form a tighter cluster of small inclusions (Figure 26).

Next, we wanted to validate results of the AA competitive inhibition screen that suggested only structurally similar AAs (Ile, Leu, Val or Ala, Cys, Ser) mediate competitive inhibition and rescue of Sip2. HeLa cells were infected with Sip2 and then treated with either 10 mM Ile and Ala or Ser and Val. We confirmed that the addition of 10 mM Ala does not alleviate AA starvation caused by Ile treatment, as Sip2 still formed significantly smaller inclusions than L2-GFP ($p < .0001$) (Figure 27). Similarly, Ser treatment still caused Sip2 to form small inclusions when co-treated with 10 mM Val (Figure 28). These results indicated that excess Ile exclusively antagonizes the transport of Val, while excess Ser only inhibits the transport of Ala. These results support the hypothesis that CTL0225 is involved in the transport of two classes of AA that have not been previously described as limited during IFN-$\gamma$ mediated persistence.

**IFN-$\gamma$ depletes free amino acid pools**

Our competitive inhibition assays suggested that free AA may be limiting during IFN-$\gamma$ mediated persistence. HPLC-mass spectrometry was used to determine if free AA pools in HeLa cells deplete over time in ± IFN-$\gamma$ conditions. Untreated and IFN-$\gamma$ treated monolayers were pelleted and weighed at each time point indicated. Following cell lysis, proteins were precipitated, and free AAs
were isolated from the supernatant. The concentration of free AAs was normalized to cell pellet weight to control for variability between samples. The average concentration of free AAs collected from 3 biological replicates was then compared between ± IFN-γ conditions.

Initially, we wanted to determine if free AA concentrations fluctuated during normal HeLa cell growth. If free AA concentrations fluctuated over time during normal growth, then this could confound our interpretations about the availability of free AA when HeLa cells are treated with IFN-γ and/or infected with *C. trachomatis*. Metabolomics analysis of normally growing HeLa cells suggested that the concentrations of free AAs were stable (Figure 29).

Next, we wanted to determine if IFN-γ depletes free AA in HeLa cells. Most AA decreased over time in IFN-γ treated HeLa cells (Figure 30). This observation led us to speculate that CTL0225 may circumvent host AA limitation during IFN-γ mediated persistence. Additionally, we observed that the concentration of free Trp was the low at every time point assayed in IFN-γ treated cells compared to untreated HeLa cells (Figure 31). This result suggested that IDO1 was the only host factor actively degrading an AA. Furthermore, we speculate general AA depletion, caused by IFN-γ treatment, might be due to an increase in protein synthesis and charging of unbound tRNAs.

**C. trachomatis increases free amino acid pools**

Sip2 has normal growth kinetics in the absence of IFN-γ (Figure 10), indicating that CTL0225 is nonessential during normal growth. Additionally, this suggests free AA pools are not limiting during *C. trachomatis* infection. To test this hypothesis, we used HPLC-mass spectrometry to determine the free AA concentrations in uninfected and infected HeLa cells over time, as described...
above. The concentration of free AA was higher in *C. trachomatis* infected HeLa cells as compared to uninfected cells, 24 and 36 hpi (Figure 32). These results indicate *C. trachomatis* infection causes an increase in free AA and suggest that having multiple AA transporters may be dispensable during normal growth.

**IFN-γ decreases AA pools in *C. trachomatis* infected cells**

Lastly, we tested if *C. trachomatis* could increase free AA pools in IFN-γ treated HeLa cells. Free AA concentrations were determined as described above and compared to uninfected HeLa cells. The concentration of most of the free AAs resembled what was observed in uninfected IFN-γ treated HeLa cells by 24 hpi (Figure 33). This result showed that *C. trachomatis* did not counteract the effects of IFN-γ to decrease free AA pools. Additionally, all the AA CTL0225 may transport, specifically Ile, Leu, Val, Ala, Cys, and Ser, were decreased 24 hpi. These observations support the hypothesis that AA transporters, such as CTL0225, are essential for survival during IFN-γ mediated persistence.
Figure 21. G77E alters CTL0225 membrane topology. (A) Membrane topology of wild type CTL0225. (B) G77E in Sip2 is predicted to disrupt the third transmembrane helix of CTL0225. TMHMM Server 2.0 predicted transmembrane orientation and TOPO2 display software.
Figure 22. Sip2 is sensitive to high concentrations of Ile. All of the indicated strains make smaller inclusions in response to increasing concentrations of isoleucine. L2-GFP, Sip1, Sip6 and rSip2 make similar sized inclusions at the same Ile concentrations. In contrast, Sip2 makes significantly smaller inclusions when compared to L2-GFP. Bars represent mean inclusion size. n=3. At least 1000 inclusions for each strain were analyzed. Error bars indicate SD. ****, p < .0001
Figure 23. Only Val reverses the Sip2 small inclusion phenotype. The strains were treated with 10mM Ile in the presence of increasing concentrations of either (A) Val, or (B) Leu. The addition of 5mM Val was sufficient to allow Sip2 to form large inclusions when co-treated with 10mM Ile. However, increasing concentrations of Leu did not allow Sip2 to form large inclusions when co-treated with Ile. Bars represent mean inclusion size. n=3. At least 500 inclusions for each strain were analyzed. Error bars indicate SD. ****, $p < .0001$
Figure 24. Ala reverses formation of small inclusions induced by excess Ser. HeLa cells were infected with the above strains and were either left untreated or treated with 10 mM Ser, or 10 mM Ser + Ala. Sip2 formed significantly smaller inclusions that L2-GFP and rSip2 strains when treated with Ser alone and this phenotype was reversed with the addition of 10 mM Ala. Bars represent the mean inclusion size of at least 1000 inclusions. n=3. Error bars indicate SD. ****, p <.0001.
Figure 25. Ala reverses Sip2 small inclusion phenotype caused by Cys. HeLa cells were infected with the indicated strains and were either left untreated or treated with 10 mM Cys or 10 mM Cys + Ala. Sip2 formed significantly smaller inclusions than L2-GFP and rSip2 when treated with Cys alone. Sip2 formed large inclusions when co-treated with 10 mM Cys and Ala. Bars represent the mean inclusions size of at least 1000 inclusions. n=3. Error bars indicate SD. ****, p < .0001. n.s. non-significant.
Figure 26. Sip2 forms two populations of inclusions when treated with Ser. Sip2 infected cells were treated with 10 mM Cys, Ser, Ile, or Leu. Infected monolayers were fixed 44-48 hpi, and the area of each inclusion was determined. Measurements of individual inclusion sizes are depicted. The average and standard deviation of inclusion sizes in each condition are represented by the indicated lines. At least 500 Sip2 inclusions were measured for each treatment condition.
Figure 27. Ala does not reverse the small inclusion phenotype caused by Ile. Hela cells were infected with L2-GFP, Sip2, and rSip2, and were either left untreated or treated with 10 mM Ile and Ala. The small inclusion phenotype caused by Ile treatment was not reversed with the addition of Ala. Bars represent the mean inclusions size of at least 1000 inclusions. n=3. Error bars indicate SD. ****, *p* < .0001. n.s. non-significant.
Figure 28. Sip2 does not form large inclusions in the presence of Val + Ser. The indicated strains were used to infect HeLa cells that were left untreated, treated with 10 mM Ser or 10 mM Ser + Val. These are representative images from one experiment. Inclusions were stained with anti-chlamydial LPS and Alexa Flour 488 secondary antibody. FIJI was used to adjust brightness and contrast.
Figure 29. Free AA concentrations remain stable over time. Uninfected and untreated HeLa cells were harvested at the indicated time points and free AA were quantified using HPLC-Mass spectrometry. Concentrations were normalized to an internal standard, and mg cell weight. Bars represent the mean concentration from three replicate samples. Error bars indicated SD.
Figure 30. Free AA decrease over time in IFN-γ treated HeLa cells. HeLa cells were treated for 24 hours with IFN-γ. This time point was redefined as time zero. Free AA were collected and quantified at the indicated time points. Concentrations of the majority of the AAs decreased over time. Bars represent the mean of three replicate samples. Error bars indicated SD.
Figure 31. IFN-γ decreases free AA pools in HeLa cells. Free AA concentrations were compared between untreated and IFN-γ treated HeLa cells at the indicated time points. IFN-γ treatment decreased all free AA pools by 36 hours. Bars represent the average free AA concentrations of three replicate samples normalized to uninfected HeLa cells.
Figure 32. *C. trachomatis* increases some free AA pools. Free AA concentrations were compared between uninfected and L2-GFP infected HeLa cells. Pools of some AAs progressively increased in infected cells over time as compared to uninfected HeLa cells. Bars represent the average free AA concentrations of three replicate samples normalized to uninfected HeLa cells.
Figure 33. Free AAs do not increase during IFN-γ mediated persistence. HeLa cells were treated with IFN-γ for 24 hours and then infected with L2-GFP. Monolayers were collected, and the concentration of free AAs was determined as described above. Free AAs pools were compared between *C. trachomatis* infected + IFN-γ treated HeLa cells and untreated HeLa cells. Most AA pools decreased over time. Bars represent the average free AA concentrations of three replicate samples normalized to uninfected HeLa cells.
Chapter VI:
Discussion

Caveats in chlamydial genetics

In the past decade, there have been significant advances in the development of chlamydial genetic tools such as transformation, complementation, and allele mapping [40, 100, 135, 136]. Despite these recent advances in chlamydial genetics, several challenges for genetically manipulating Chlamydia spp. remain.

CaCl$_2$ based transformation efficiency of strains containing the endogenous chlamydial plasmid and the transformation of large shuttle plasmids still needs improvement. Curing the endogenous plasmid may improve transformation efficiency, but this is a laborious process that takes many rounds of passaging with sub-inhibitory concentrations of novobiocin [137]. Reducing the shuttle plasmid size by eliminating nonessential $pgp$ genes could increase transformation efficiency; however, the side effects of eliminating these genes has not been fully explored [138]. An alternative approach is to use a more efficient method of introducing large plasmids into $C. trachomatis$. A known method of transforming large plasmids into bacteria is electroporation [139]. Additionally, this approach has previously been used to transform $C. trachomatis$ with shuttle plasmids [140]. Thus, electroporation may be worth revisiting as a more efficient method of introducing large plasmids into Chlamydia.

Complementation in $C. trachomatis$ is another genetic tool that is in its infancy. Only three mutant genes have been complemented in $C. trachomatis$ [100, 102, 106]. However, it is unknown how the overexpression of chlamydial
proteins affects chlamydial fitness. The problem with existing complementation methods is that they introduce the gene of interest at a non-physiological copy number. Gene dosage toxicity caused by overexpression of proteins has been observed in other organisms [141, 142], suggesting elevated concentrations of chlamydial proteins may be deleterious to chlamydial fitness.

A possible way to mitigate gene dosage toxicity is to use an inducible system. A Tet-inducible GFP system, recently developed in *C. trachomatis*, only expresses GFP when ATc is present in the medium [143]. However, the authors indicate this system is leaky. While this may not affect the results of complementation experiments, the “leakiness” of the Tet-inducible system should be considered when interpreting some results. A possible way of limiting the “leakiness” of the Tet promoter is to increase binding of the tetracycline repressor (TetR) to the shuttle plasmid by introducing additional Tet response elements upstream of the Tet promoter.

Mapping mutant alleles in *C. trachomatis* is challenging. Antibiotic LGT has been used to generate recombinants and map alleles [110, 116]. However, this method has some limitations such as the limited number of chromosomal genes that confer resistance to antibiotics and the fact that antibiotic resistance decreases chlamydial fitness [144, 145]. For example, *rpoB* and *gyrA* are routinely mutated to confer resistance to rifampicin and ofloxacin, respectively [110, 116, 144, 146, 147]. However, mutations in *rpoB* and *gyrA* inhibit growth and development [121, 122]. Additionally, mutating the chlamydial 16S rRNA gene confers resistance to spectinomycin and kasugamycin; however, mutating this gene also decreases chlamydial fitness [124, 148]. Thus, antibiotic LGT is not an ideal mapping strategy for mutants whose phenotype is tied to
development because recombinants generated using this method will have growth defects.

**Limitations of identifying Sip mutants and mapping persistence genes**

The purpose of the persistence screen was to identify genes *C. trachomatis* uses to enter, maintain, and reactivate from IFN-γ mediated persistence. We were only able to isolate six Sip mutants and all of these mutants had mutations in different genes, which suggests that our screen was not saturated. This result is likely linked to the concentration of EMS we used to mutate L2-GFP. We used a low concentration of EMS to mutate L2-GFP because we wanted fewer mutations in each Sip mutant [109]. Having fewer mutations per genome would make mapping the deleterious persistence mutations easier by LGT. Alternatively, mapping could have been facilitated by performing a screen of minimally mutagenized mutants but this would have increased screen size.

We chose not to use antibiotic LGT to map the deleterious persistence mutations in the Sip mutants because the persistence phenotype is related to chlamydial development and we found introducing resistance mutations into *rpoB* and *gyrA* confounded our persistence screen results. To circumvent the limitations of antibiotic LGT we developed a counterselection LGT approach, which does not use selective antibiotic markers. The main premise behind counterselection LGT is that chlamydiae naturally recombine their genomes at a low frequency [149]; however, the trick is enriching for these rare recombinants.

We have noticed counterselection LGT works best with mutants that have strong phenotypes related to EB production. For example, the Sip mutants that we could map (Sip1, Sip2, Sip6) generate almost no infectious progeny following
reactivation from persistence with indole. In contrast, we could not map the Sip mutants that made 25 to 50% of EBs (Sip3, Sip4, Sip5), as compared to L2-GFP (Figure 11). These results suggest the main limitation of counterselection LGT is that enrichment of recombinants depends heavily on mutant EB production, which influences the strength of selection. Additionally, these results indicate a more robust LGT technique needs to be developed to map the deleterious persistence mutation in these types of Sip mutants or the enrichment strategy needs to be more carefully designed. A possible way of improving upon counterselection LGT is to recombine mutants such as Sip3 with other mutants that make fewer EB such as Sip1, or with conditional temperature-sensitive mutants, which make little to no EB at 42°C [111].

**Mutant tryptophan synthase in Sip1 may be detrimental**

One of the Sip mutants identified in the persistence screen had a P221S mutation in TrpB (TrpB\textsuperscript{P221S}). Isolating a Sip mutant with a mutation in a TS related gene was expected. However, this mutant does not fully reactivate from IFN-\(\gamma\) mediated persistence with Trp (Figure 15). This result was surprising because a *C. trachomatis* serovar D mutant that contains a null mutation in TrpB can fully reactivate by Trp from IFN-\(\gamma\) mediated persistence [109]. This result suggests that either the persistence model we used differs from the model used by Kari *et al.* or TrpB\textsuperscript{P221S} may not ablate the function of TrpB but cause toxicity that is not resolved by the addition of Trp.

In the absence of indole, the \(\beta\)-subunit of TS favors a side reaction that hydrolyzes Ser into pyruvate, ammonia, and H\(_2\)O [126]. Normally, indole is shuttled from the \(\alpha\)-subunit to the active site of the \(\beta\)-subunit through a hydrophobic tunnel. Once at the active site of the \(\beta\)-subunit, indole interacts
with an aminoacrylate intermediate, formed by the β-elimination of OH from Ser, to synthesize Trp [150-152]. However, disrupting the hydrophobic tunnel between the α- and β-subunits can allow H₂O molecules to enter the active site of the β-subunit. When this occurs, H₂O hydrolyzes the aminoacrylate intermediate to produce pyruvate and ammonia [153].

We speculate that the P221S mutation, located on the periphery of TrpB, may cause a conformational change that prevents the shuttling of indole and may allow H₂O to leak into the active site of the β-subunit. This hypothesis is supported by suppressor analysis, which indicates a suppressor mutation (Q52P), also located on the periphery of TrpBP²²²¹S, may restore the substrate tunnel (Figure 19). We observed that Sip1 genomes replicate more rapidly during Trp compared to indole reactivation. This result suggests that TrpR (repressor of TS operon) is dampening expression of TrpB²²²¹S, resulting in lower ammonia production due to less TS expression. This hypothesis could be test by inducing expression of TrpR during IFN-γ mediated persistence may allow Sip1 to reactivate with Trp [74, 109, 154, 155].

**CTL0694 may be involved in DNA damage repair**

CTL0694 is an oxidoreductase that is similar to CysJ. In *E. coli*, CysJ forms a multimeric complex with CysI (CysJ₆CysI₄) through its FMN domain and plays a critical role in the sulfite reductase pathway. However, CTL0694 lacks an FMN domain, and *C. trachomatis* does not encode an obvious CysI homologue, suggesting CTL0694 is not playing a role in sulfite reduction.

Recently, *E. coli* CysJ has been shown to have a secondary function. By forming a complex with YcbX, the CysJYcbX complex plays a critical role in detoxifying N-hydroxylated nucleobases, such as 6-N-hydroxylaminopurine
Enzymes that detoxify HAP-like nucleobases have been observed in phylogenetically diverse organisms ranging from green algae to humans, suggesting most organisms need to detoxify mutagenic nucleobase analogs.

Humans naturally generate HAP-like nucleobase analogs in the presence of oxidative radicals. To reduce incorporation of toxic nucleobase analogs into replicating DNA, humans encode mitochondrial amidoxime reducing component (mARC) 2 which is capable of converting these toxic analogs into non-toxic bases. However, this system may become overwhelmed in the presence of IFN-γ because IFN-γ is known to increase the generation of oxidative radicals. Thus, during IFN-γ mediated persistence, C. trachomatis may need to rely on nucleobase detoxifying enzymes to prevent incorporation of toxic nucleobases during genome replication.

We speculate that CTL0694 is playing a critical role in preventing incorporation of toxic nucleobases into replicating genomes during IFN-γ mediated persistence, as chlamydiae scavenge purines and pyrimidines from host nucleotide pools. Failure to detoxify these nucleobases in the presence if IFN-γ could explain why Sip6 makes smaller inclusions than L2-GFP in IFN-γ + excess tryptophan conditions (Figure 16). Additionally, it could explain why Sip6 makes similar numbers of genomes as L2-GFP but produces fewer infectious progeny following reactivation with either Trp or indole (Figure 14). Lastly, we hypothesize that the P105L mutation in Sip6 may be inducing a conformational change that is preventing CTL0694 from binding to a YcbX-like protein. Protein-protein interaction assays could elucidate what CTL0694 binds.
during IFN-γ mediated persistence and provide insight into what role CTL0694 plays in IFN-γ ± conditions.

**Chlamydia increase AA during normal development**

Intracellular pathogens are known to encode effectors that increase the concentration of free AA. For example, *Legionella pneumophila* injects Ankyrin-B, a type IV effector, into the host cytoplasm to hijack host polyubiquitination and protein degradation machinery. When this occurs, degradation of host proteins increases, and there is a significant increase in free AA levels [164, 165]. Like *L. pneumophila*, *C. trachomatis* may increase free AA concentrations (Figure 32). However, it is unknown if the increase in free AA pools is caused by *C. trachomatis* or the host response to infection. Many of these host proteins are involved in cellular growth and proliferation [166], suggesting increased host AA transport may play a role in increasing free AA pools. Additionally, these results support the hypothesis that AA transporters, such as CTL0225, are dispensable during normal growth due to sufficient AA concentrations.

**Amino acid transport in Chlamydia**

There are only a few AA transporters annotated in the chlamydial genome. The chlamydial MtR homologue TyrP may transport Trp and tyrosine (Tyr), although this has never been verified. The only characterized chlamydial AA transporter is CTL0817, a BrnQ homolog. Chlamydial BrnQ transports Val and may be involved in the transport of Ile, Leu, Phe, and Met, as determined by AA competitive inhibition assays [67]. Notably, chlamydial BrnQ has expanded substrate specificity. In other bacteria, BrnQ only transports BCAA [132, 167], but in *Chlamydia* it may also transport Phe and Met [67]. Our results suggest CTL0225 is another AA transporter with expanded substrate specificity.
**CTL0225 is likely a component of two AA transport systems**

Sip2 formed significantly smaller inclusions than L2-GFP when treated with a high concentration of Ile, Leu, Ser or Cys. As discussed in the introduction, a high concentration of one AA can block the transport of another similar AA. When competitive inhibition occurs, subsequent AA starvation induces *C. trachomatis* to form small inclusions. Consistent with this, when Sip2 is treated with Ile, Leu, Ala, or Ser it forms small inclusions. However, when Sip2 is co-treated with Val + either Ile or Leu, or Ala + either Ser or Cys, it forms large inclusions. Thus, CTL0225 is likely an AA transporter that is involved in the transport of BCAA, Ala, Cys, and Ser across the chlamydial inner membrane. These AAs have not been previously shown to be transported together [168, 169]. This observation suggests that CTL0225 may be a component of two distinct transporters.

CTL0225 has an upstream paralog, CTL0226. Both of these proteins are predicted to be members of the small neutral amino acid transporter (SNAT) family. This family of proteins is predicted to contain six transmembrane domains [170]. Like SnatA, CTL0226 is also predicted to contain six transmembrane domains.

SnatA family members are also predicted to transport neutral AAs. Recombinant SnatA transports Gly, whose transport can be competitively inhibited by a broad range of neutral AAs. Ala, Ser, and Cys, were amongst the strongest inhibitors (>80%) of Gly transport [171]. These observations are consistent with our competitive inhibition data that suggests CTL0225 may be involved in the transport of Ala, Ser, and Cys in *C. trachomatis*. Interestingly, Ile, Leu, and Val also weakly inhibit Gly transport. However, because most BCAA
transporters are predicted to have 12 transmembrane domains [134, 172], and Sip2 shows distinct competitive inhibition of Val transport by Ile and Leu, we speculate that CTL0225 may form a homodimer or heterodimer with its paralogue CTL0226 to transport BCAA.

SnatA mediated Gly transport was 60% inhibited by Trp [171]. We speculate that CLT0225 may also be involved in the transport of Trp. However, we were unable to test this because high concentrations were cytotoxic to HeLa cells. Additionally, we observed that the Sip2 mutant made fewer inclusions than L2-GFP following reactivation with Trp, suggesting Sip2 could not make proteins critical for survival and reactivation due to the inefficient transport of Trp and the above-mentioned AAs.

**IFN-γ restricts host free AA pools**

Chlamydiae are auxotrophic for many AA and are highly dependent on their host cells for nutrients [78, 173]. Depleting or limiting the availability of AA, such as BCAA, Trp, and phenylalanine can inhibit chlamydial development and induce entry into persistence [72, 174, 175]. It is unknown how host AAs traverse the inclusion membrane or if chlamydiae actively or passively transport AAs once they are inside the inclusion lumen. However, it is known that cycloheximide can enhance chlamydial development by increasing free cytosolic AAs pools by inhibiting host protein synthesis [173, 176]. Additionally, chlamydiae incorporate radiolabeled AA added to cell culture medium [177]. These data suggest AA concentrations in the host cell cytoplasm can affect AA availability within the chlamydial inclusion. Thus, in AA limiting conditions chlamydial AA transporters may become important.
The broad specificity of AA substrates that CTL0225 may transport suggested AAs are limiting during IFN-γ mediated persistence. Our metabolomics data indicate IFN-γ treatment causes all free AAs to decrease over time as compared to untreated cells (Figure 30). This observation was surprising because IFN-γ has not been shown to deplete AAs other than Trp [178]. Additionally, IFN-γ induces autophagy, which maintains critical levels of AAs for cell host survival by degrading host proteins [179]. This is consistent with our metabolomic data, which suggests IFN-γ treatment causes the depletion of AAs in HeLa cells over time. Additionally, these results support the hypothesis that C. trachomatis may encode multiple AA transporters and effectors to counter AA starvation caused by IFN-γ mediated AA depletion.

Overall, we have validated the hypothesis that C. trachomatis has mechanisms, besides tryptophan synthesis, to circumvent the effects of IFN-γ mediated persistence. We have identified two additional genes that play a role in IFN-γ mediated persistence. We hypothesize that CTL0694 plays a critical role in C. trachomatis reactivating from persistence because Sip6 makes similar numbers of genomes as L2-GFP but is unable to transition from aberrant RB back into EB. Identifying the protein partner of CTL0694 is paramount to understanding its role during persistence. CTL0225 is an AA transporter with a broad substrate specificity that becomes necessary during AA limiting conditions. Metabolomics data indicate for the first time that free AA pools decreased over time in HeLa cells treated with IFN-γ treatment, and that the active or passive mechanisms of AA depletion in eukaryotic cells should be investigated. Additionally, chlamydial effectors that increase AA concentrations should be identified and tested as they may function as nutritional virulence
factors. Lastly, we have described a TS mutant that may produce ammonia instead of Trp. This mutant could test the hypothesis that ocular strains of *Chlamydia* have inactivated TS to avoid ammonia production in the absence of indole.
Chapter VII:

Future Directions

Constructing a larger library to screen for additional Sip mutants

We identified only 6 Sip mutants from our persistence screen. These mutants did not have overlapping mutations, indicating the screen was unsaturated. A larger mutant library needs to be constructed to identify additional Sip mutants. However, making a larger library by plaque cloning is cost prohibitive, time-consuming, and labor-intensive. Fluorescence-activated cell sorting (FACS) is a fast and robust tool that has been used to sort cells infected with a GFP-expressing *Rickettsia prowazekii* [180] and cells containing fluorescently labeled *C. trachomatis* inclusions [181, 182]. Additionally, FACS has been used to sort single cells into individual wells [183, 184]. These studies indicate that cells infected with GFP-expressing *C. trachomatis* could be quickly sorted into individual wells by FACS to make a large mutant library.

Mapping additional Sip mutant persistence alleles

We were unable to map the deleterious persistence alleles in Sip3, Sip4, and Sip5 by recombining them with each other (Sip3 x Sip4, Sip3, x Sip5, Sip4 x Sip5). However, it may be possible to map these alleles by altering the recombination scheme. By recombining these mutants with mutants that make little to no EB, such as Sip1, or Sip6 it may be possible to map the remaining persistence alleles. Alternatively, reverse genetic techniques could also be used to map the deleterious persistence alleles.

Determine if autophagy is involved in clearing persistent inclusions

L2-GFP forms fewer inclusions following reactivation from persistence compared to when it infects untreated HeLa cells. However, it is unknown how
cells are clearing inclusions during persistence. A possible mechanism that cells use to clear inclusions is autophagy. IFN-γ induces autophagy and the formation of autophagosomes that localize with lysosomes [185]. Additionally, IFN-γ induces expression of human guanylate binding proteins 1 and 2, which associate with the chlamydial inclusion and facilitate fusion with autophagosomes [186]. These studies suggest that during IFN-γ mediated persistence cells induce autophagy to clear chlamydial inclusions.

To test the hypothesis that IFN-γ is inducing autophagy to clear inclusions during persistence, wild-type and KO cell lines lacking key autophagy proteins, such as ATG7 or ATG16, could be treated with IFN-γ and infected with L2-GFP [187]. If autophagy is playing a key role in the clearance of inclusions during persistence, then the autophagy KO cell lines should have more inclusions than wild-type cells.

Fluorescent microscopy could also be used to monitor autophagosome formation in wild-type and autophagy KO cell lines. LC3 is an autophagosomal marker that associates with autophagosomes. If autophagosomes are clearing chlamydial inclusions in wild-type cells during persistence, then LC3 should colocalize with chlamydial inclusions. Conversely, in autophagy KO cell lines LC3 should not colocalize with chlamydial inclusions.

**Determine if Sip1 is degrading mutant TrpB**

We have not determined if TrpB^{T231S} is being expressed at similar concentrations as wild-type TrpB during persistence. Western blot analysis can be used to compare expression of wild-type and mutant TrpB; however, we do not have an antibody to chlamydial TrpB. Alternatively, we can place an N- or C-terminal His-tag on TrpB and mutant TrpB, and express these proteins from a
shuttle plasmid, using their native promoter, in a $\Delta trpB$ *C. trachomatis* background. An anti-His antibody could then be used to detect wild-type TrpB, and mutant TrpB by Western blot and relative expression could be quantified by densitometry [188].

**Assess if mutant TrpB produces ammonia**

In the absence of indole the $\beta$-subunit of TS can slowly hydrolyze Ser to pyruvate and ammonia [153]. We hypothesize that mutant TrpB (TrpB$^{P221S}$) cannot utilize indole and is producing ammonia instead of Trp. Mutant and wild-type TS could be expressed and purified from *E. coli* [155]. By mixing purified wild-type and mutant TS with Ser and indole, ammonia and Trp should be produced [126, 189]. The concentration of ammonia and Trp can be quantified using HPLC [190].

**Determine if TrpB$^{P221S}$ expression is deleterious for chlamydial growth**

If TrpB$^{P221S}$ is deleterious to chlamydial growth, then strains that express TrpB$^{P221S}$ should make smaller inclusions and fewer EB than strains expressing TrpB. Wild-type and mutant *trpB* genes, placed under control of an inducible promoter, could be expressed from a shuttle vector in the presence of indole in a $\Delta trpB$ *C. trachomatis* background. As a control, $\Delta trpB$ *C. trachomatis*, harboring an empty vector, should be assessed in parallel with TrpB and TrpB$^{P221S}$-expressing strains. If TrpB$^{P221S}$ is deleterious to chlamydial growth, then it should make smaller inclusions and less EB than strains expressing wild-type TrpB or the empty vector.

**Determine CTL0694 interacting partners and function**

CTL0694 is predicted to be an oxidoreductase that provides reducing electrons to an unknown protein during IFN-$\gamma$ mediated persistence.
Determining what protein CTL0694 binds to will help to define the role of CTL0694 during normal growth and IFN-\(\gamma\) mediated persistence. By expressing wild-type and mutant CTL0694 (CTL0694\(^{\text{P105L}}\)) in \(C.\ trachomatis\) during normal growth and IFN-\(\gamma\) mediated persistence, co-immunoprecipitation assays could be used to isolate proteins that interact with CTL0694. Mass spectrometry and database mining could then be used to identify the interacting protein partners and help us to define the role CTL0694 plays during persistence. Additionally, we could also compare the binding partners between wild-type and CTL0694\(^{\text{P105L}}\) to determine if the P105L mutation disrupts protein-protein interactions.

**Determine if Sip2 expresses CTL0225\(^{G77E}\) during IFN-\(\gamma\) mediated persistence**

Loss of the third transmembrane domain of CTL0225 likely inhibits AA transport function. However, it may be possible that the G77E mutation induces transcriptional degradation, translational silencing, or post-translational degradation of mutant CTL0225 (CTL0225\(^{G77E}\)). Quantitative PCR can be used to detect mutant CTL0225 mRNA expression levels to confirm that CTL0225\(^{G77E}\) is still being transcribed throughout normal development and during IFN-\(\gamma\) mediated persistence. However, since we do not have an antibody to CTL0225, we cannot readily determine if CTL0225\(^{G77E}\) is post-translationally degraded. An alternative approach to creating an antibody to CTL0225 would be to fuse an epitope tag to the N- or C- terminal end of CTL0225\(^{G77E}\) and express it under its endogenous promoter from a shuttle plasmid. If this protein is being expressed and not degraded, it should be detectable by Western blot.

While it is suggestive that the G77E mutation causes the loss of function of CTL0225, it may be possible that this mutation causes translational silencing or post-translational degradation of mutant CTL0225. Quantitative PCR can be
used to detect mutant CTL0225 mRNA expression levels to confirm that CTL0225<sup>G77E</sup> is still being transcribed throughout normal development and during IFN-γ mediated persistence. However, determining if Sip2 is post-translationally degrading CTL0225<sup>G77E</sup> is more challenging since we do not have a CTL0225 antibody. As an alternative approach to making an antibody, we could fuse an N- or C- terminal epitope tag to CTL0225 and CTL0225<sup>G77E</sup> and express these proteins under their endogenous promoter from a shuttle plasmid. If CTL0225<sup>G77E</sup> is being expressed and not degraded, it should be detectable by Western blot. Additionally, we can determine if CTL0225 forms a homodimer or heterodimer with CTL0226 by comparing native and SDS-PAGE gels.

**Confirm CTL0225 transports amino acids**

We hypothesize that the CTL0225 transports Ser, Cys, and Ala, while a homodimer or heterodimer of CTL0225 + CTL0226 is responsible for the transport of Leu, Ile, and Val. To directly assess the substrate specificity of these proteins we could use radiolabeled (C<sup>14</sup>) AA in AA transport assays. We can clone these chlamydial genes into *E. coli* expression vectors and then transform these recombinant plasmids into strains of *E. coli* that cannot transport Ser or BCAA. By assessing radioactivity uptake in competitive inhibition assays with “cold AA,” we can determine how well these proteins transport each AA.

**Determine if Sip2 is sensitive to low concentrations of AA**

Metabolomics analysis of IFN-γ treated HeLa cells suggest AA are limiting during IFN-γ mediated persistence. Having multiple AA transporters may help to circumvent the effects of low AA concentrations. To test the hypothesis, HeLa cells could be incubated in DMEM-10 with no AA for 24 hours, to deplete AA,
and then infected with L2-GFP, Sip2, or rSip2. Inclusion sizes and EB production can then be compared at 24, 36, and 48, hpi. If Sip2 makes smaller inclusions and less EB than L2-GFP or rSip2, then it would suggest that Sip2 is not able to fully reactivate from persistence because of AA starvation and because it expresses a non-functional CTL0225.
REFERENCES


42. Grieshaber SS, Grieshaber NA, Hackstadt T. Chlamydia trachomatis uses host cell dynein to traffic to the microtubule-organizing center in a p50


65. Kuo CC, Grayston JT. Amino acid requirements for growth of Chlamydia pneumoniae in cell cultures: growth enhancement by lysine or


147. Suchland RJ, Sandoz KM, Jeffrey BM, Stamm WE, Rockey DD. Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.


169. Short SA, White DC, Kaback HR. Mechanisms of active transport in isolated bacterial membrane vesicles. IX. The kinetics and specificity of


CURRICULUM VITAE

Matthew Kazuyuki Muramatsu

EDUCATION

Ph.D. Microbiology 2013-2017
Department of Microbiology and Immunology
Indiana University, Indianapolis, IN

Ph.D. Microbiology 2011-2012
Department of Biology-Microbiology Program
Indiana University, Bloomington, IN

B.S. Microbiology 2005-2009
Department of Microbiology
University of Washington, Seattle, WA

RESEARCH EXPERIENCE

Graduate Research Assistant 2013-2017
Department of Microbiology and Immunology
Indiana University School of Medicine, Indianapolis, IN
Pl: David Nelson, Ph.D.
- Investigating the different mechanisms C. trachomatis uses to circumvent intracellular stressors such as nutrient deprivation and the effects of IFN-γ mediated persistence.

Graduate Research Assistant 2011-2012
Department of Biology
Indiana University, Bloomington, IN
Pl: David Nelson, Ph.D.
- Optimized transformation, plasmid curing, and chemical mutagenesis conditions for C. trachomatis.

Research Scientist 2010-2011
Department of Immunology
University of Washington, Seattle, WA
Pl: Michael Gale Jr., Ph.D. NIAID: 272200900035C-2-0-1
- Investigated how novel adjuvant compounds stimulated the innate immune system in cell culture and animal models.

Undergraduate Research Technician 2008-2009
Northwest Fisheries Science Center
National Oceanic and Atmospheric Administration, Seattle, WA
P.I.: Mark Strom, Ph.D.
- Used Multi-Locus Sequence Typing to determine the genetic phylogeny of Vibrio parahaemolyticus isolates.
PROFESSIONAL EXPERIENCE

Microbiologist  2009-2010
Institute of Environmental Health, Lake Forest Park, WA
- Co-led a Federal Drug Administration project investigating the number and type of bacteria found in ready to eat leafy greens.
- Used molecular and culture based techniques to identify harmful pathogens present in food.

GRANT & AWARD

Microbial Pathogenesis and Host Response Travel Award  2015
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Genetic, Cellular and Molecular Sciences Training Grant  2011-2012
National Institute of General Medical Sciences, National Institute of Health NIGMS Training Grant 5T32GM007757-32

PUBLICATIONS


INVITED TALK


CONFERENCE PRESENTATIONS


**TEACHING EXPERIENCE**

**Associate Instructor**
Evolution and Diversity, Indiana University, Bloomington, IN  
Fall 2011

**AFFILIATION**

The American Society of Microbiology: Member  
2009-Pres.

**SERVICE**

Research in progress award committee chair  
2014